# PeptideScanner evidence objects: Eptifibatide

Every published version of the records placed with Eptifibatide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json. Selected public evidence only; not medical advice.

- Objects: 64
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00061373-eptifibatide-v1"></a>

## ClinicalTrials.gov record NCT00061373

> PeptideScanner retained ClinicalTrials.gov record NCT00061373 at 2026-11-15T21:59:29.646Z. Its registry update date was 2013-02-04, and PeptideScanner's reviewed identity mapping was eptifibatide.

- Evidence object: `story:clinicaltrials-gov-nct00061373-eptifibatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-02-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00061373-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct00061373-eptifibatide-v1
- Content SHA-256: `9d3c478d45f0b715cfb44f7f73b4f85bbef03b2de86abf1de5e08dbac0d8d862`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00061373 ([`ctg-observation-nct00061373-2013-02-04-3ef2f1793370`](#source-ctg-observation-nct00061373-2013-02-04-3ef2f1793370))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00061373 at 2026-11-15T21:59:29.646Z. Its registry update date was 2013-02-04, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct00061373-2013-02-04-3ef2f1793370`](#source-ctg-observation-nct00061373-2013-02-04-3ef2f1793370))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00061373 at 2026-11-15T21:59:29.646Z. Its registry update date was 2013-02-04, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct00061373-2013-02-04-3ef2f1793370`](#source-ctg-observation-nct00061373-2013-02-04-3ef2f1793370))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00061373-2013-02-04-3ef2f1793370`](#source-ctg-observation-nct00061373-2013-02-04-3ef2f1793370))

### Sources

<a id="source-ctg-observation-nct00061373-2013-02-04-3ef2f1793370"></a>
- **ClinicalTrials.gov record NCT00061373 · retained source version 2013-02-04:3ef2f1793370ca1e04967a7e310e191272008f7016799ccbfdf8e68f1fc0662f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00061373) (`ctg-observation-nct00061373-2013-02-04-3ef2f1793370`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00061373." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct00061373-eptifibatide-v1 SHA-256: 9d3c478d45f0b715cfb44f7f73b4f85bbef03b2de86abf1de5e08dbac0d8d862.

---

<a id="clinicaltrials-gov-nct00089895-eptifibatide-v1"></a>

## ClinicalTrials.gov record NCT00089895

> PeptideScanner retained ClinicalTrials.gov record NCT00089895 at 2026-11-15T21:59:29.646Z. Its registry update date was 2024-05-17, and PeptideScanner's reviewed identity mapping was eptifibatide.

- Evidence object: `story:clinicaltrials-gov-nct00089895-eptifibatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-05-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00089895-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct00089895-eptifibatide-v1
- Content SHA-256: `b1b6d44dcbf8d90bd776cb1829b0767eb0ab8ca3fc4bd6e6e76f2636fe78a304`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00089895 ([`ctg-observation-nct00089895-2024-05-17-e5568f1aaf91`](#source-ctg-observation-nct00089895-2024-05-17-e5568f1aaf91))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00089895 at 2026-11-15T21:59:29.646Z. Its registry update date was 2024-05-17, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct00089895-2024-05-17-e5568f1aaf91`](#source-ctg-observation-nct00089895-2024-05-17-e5568f1aaf91))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00089895 at 2026-11-15T21:59:29.646Z. Its registry update date was 2024-05-17, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct00089895-2024-05-17-e5568f1aaf91`](#source-ctg-observation-nct00089895-2024-05-17-e5568f1aaf91))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00089895-2024-05-17-e5568f1aaf91`](#source-ctg-observation-nct00089895-2024-05-17-e5568f1aaf91))

### Sources

<a id="source-ctg-observation-nct00089895-2024-05-17-e5568f1aaf91"></a>
- **ClinicalTrials.gov record NCT00089895 · retained source version 2024-05-17:e5568f1aaf91e755421783f5d9916aff55d6725da51e460346a4780cc78bffbb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00089895) (`ctg-observation-nct00089895-2024-05-17-e5568f1aaf91`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00089895." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct00089895-eptifibatide-v1 SHA-256: b1b6d44dcbf8d90bd776cb1829b0767eb0ab8ca3fc4bd6e6e76f2636fe78a304.

---

<a id="clinicaltrials-gov-nct00111566-eptifibatide-v1"></a>

## ClinicalTrials.gov record NCT00111566

> PeptideScanner retained ClinicalTrials.gov record NCT00111566 at 2026-11-15T21:59:29.646Z. Its registry update date was 2013-11-28, and PeptideScanner's reviewed identity mapping was eptifibatide.

- Evidence object: `story:clinicaltrials-gov-nct00111566-eptifibatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-11-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00111566-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct00111566-eptifibatide-v1
- Content SHA-256: `cfc4da8710fc67dec6b46f2e076cbf2418648d92485b1b7c50a9d1e4f12b22e1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00111566 ([`ctg-observation-nct00111566-2013-11-28-175ac30eb35d`](#source-ctg-observation-nct00111566-2013-11-28-175ac30eb35d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00111566 at 2026-11-15T21:59:29.646Z. Its registry update date was 2013-11-28, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct00111566-2013-11-28-175ac30eb35d`](#source-ctg-observation-nct00111566-2013-11-28-175ac30eb35d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00111566 at 2026-11-15T21:59:29.646Z. Its registry update date was 2013-11-28, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct00111566-2013-11-28-175ac30eb35d`](#source-ctg-observation-nct00111566-2013-11-28-175ac30eb35d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00111566-2013-11-28-175ac30eb35d`](#source-ctg-observation-nct00111566-2013-11-28-175ac30eb35d))

### Sources

<a id="source-ctg-observation-nct00111566-2013-11-28-175ac30eb35d"></a>
- **ClinicalTrials.gov record NCT00111566 · retained source version 2013-11-28:175ac30eb35de924e813601d189bf2a46807f8a6feed75ace50495284874980c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00111566) (`ctg-observation-nct00111566-2013-11-28-175ac30eb35d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00111566." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct00111566-eptifibatide-v1 SHA-256: cfc4da8710fc67dec6b46f2e076cbf2418648d92485b1b7c50a9d1e4f12b22e1.

---

<a id="clinicaltrials-gov-nct00250991-eptifibatide-v1"></a>

## ClinicalTrials.gov record NCT00250991

> PeptideScanner retained ClinicalTrials.gov record NCT00250991 at 2026-11-15T21:59:29.646Z. Its registry update date was 2009-05-08, and PeptideScanner's reviewed identity mapping was eptifibatide.

- Evidence object: `story:clinicaltrials-gov-nct00250991-eptifibatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2009-05-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00250991-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct00250991-eptifibatide-v1
- Content SHA-256: `2b85044909367e68f494cd3ad0b377cfe7543bb86dae4d607bc993229281d425`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00250991 ([`ctg-observation-nct00250991-2009-05-08-c997410fea2a`](#source-ctg-observation-nct00250991-2009-05-08-c997410fea2a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00250991 at 2026-11-15T21:59:29.646Z. Its registry update date was 2009-05-08, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct00250991-2009-05-08-c997410fea2a`](#source-ctg-observation-nct00250991-2009-05-08-c997410fea2a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00250991 at 2026-11-15T21:59:29.646Z. Its registry update date was 2009-05-08, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct00250991-2009-05-08-c997410fea2a`](#source-ctg-observation-nct00250991-2009-05-08-c997410fea2a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00250991-2009-05-08-c997410fea2a`](#source-ctg-observation-nct00250991-2009-05-08-c997410fea2a))

### Sources

<a id="source-ctg-observation-nct00250991-2009-05-08-c997410fea2a"></a>
- **ClinicalTrials.gov record NCT00250991 · retained source version 2009-05-08:c997410fea2a668cf5cd5b448ba57b1823c092efc2cd840f0cbc77f5cfb079bd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00250991) (`ctg-observation-nct00250991-2009-05-08-c997410fea2a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00250991." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct00250991-eptifibatide-v1 SHA-256: 2b85044909367e68f494cd3ad0b377cfe7543bb86dae4d607bc993229281d425.

---

<a id="clinicaltrials-gov-nct00317395-eptifibatide-v1"></a>

## ClinicalTrials.gov record NCT00317395

> PeptideScanner retained ClinicalTrials.gov record NCT00317395 at 2026-11-15T21:59:29.646Z. Its registry update date was 2014-12-03, and PeptideScanner's reviewed identity mapping was eptifibatide.

- Evidence object: `story:clinicaltrials-gov-nct00317395-eptifibatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-12-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00317395-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct00317395-eptifibatide-v1
- Content SHA-256: `3eb5bbb22fec5364c80b47ef9e9f56372347a6241b173bd3e50f0b30715c2689`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00317395 ([`ctg-observation-nct00317395-2014-12-03-bff0ac8219fc`](#source-ctg-observation-nct00317395-2014-12-03-bff0ac8219fc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00317395 at 2026-11-15T21:59:29.646Z. Its registry update date was 2014-12-03, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct00317395-2014-12-03-bff0ac8219fc`](#source-ctg-observation-nct00317395-2014-12-03-bff0ac8219fc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00317395 at 2026-11-15T21:59:29.646Z. Its registry update date was 2014-12-03, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct00317395-2014-12-03-bff0ac8219fc`](#source-ctg-observation-nct00317395-2014-12-03-bff0ac8219fc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00317395-2014-12-03-bff0ac8219fc`](#source-ctg-observation-nct00317395-2014-12-03-bff0ac8219fc))

### Sources

<a id="source-ctg-observation-nct00317395-2014-12-03-bff0ac8219fc"></a>
- **ClinicalTrials.gov record NCT00317395 · retained source version 2014-12-03:bff0ac8219fc5822906db98b1c8e1b11ab336c7e62d002addfcc7212f860f86f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00317395) (`ctg-observation-nct00317395-2014-12-03-bff0ac8219fc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00317395." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct00317395-eptifibatide-v1 SHA-256: 3eb5bbb22fec5364c80b47ef9e9f56372347a6241b173bd3e50f0b30715c2689.

---

<a id="clinicaltrials-gov-nct00426751-eptifibatide-v1"></a>

## ClinicalTrials.gov record NCT00426751

> PeptideScanner retained ClinicalTrials.gov record NCT00426751 at 2026-11-15T21:59:29.646Z. Its registry update date was 2012-11-27, and PeptideScanner's reviewed identity mapping was eptifibatide.

- Evidence object: `story:clinicaltrials-gov-nct00426751-eptifibatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-11-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00426751-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct00426751-eptifibatide-v1
- Content SHA-256: `cfd7a923253e178077f69dea36b1950fc25c142d8943991d40e8668ab4f9caed`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00426751 ([`ctg-observation-nct00426751-2012-11-27-74a63272bb20`](#source-ctg-observation-nct00426751-2012-11-27-74a63272bb20))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00426751 at 2026-11-15T21:59:29.646Z. Its registry update date was 2012-11-27, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct00426751-2012-11-27-74a63272bb20`](#source-ctg-observation-nct00426751-2012-11-27-74a63272bb20))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00426751 at 2026-11-15T21:59:29.646Z. Its registry update date was 2012-11-27, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct00426751-2012-11-27-74a63272bb20`](#source-ctg-observation-nct00426751-2012-11-27-74a63272bb20))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00426751-2012-11-27-74a63272bb20`](#source-ctg-observation-nct00426751-2012-11-27-74a63272bb20))

### Sources

<a id="source-ctg-observation-nct00426751-2012-11-27-74a63272bb20"></a>
- **ClinicalTrials.gov record NCT00426751 · retained source version 2012-11-27:74a63272bb20e8e087ad0f2b1c8556e0f714d93c2a2918ade6d8ebf1232e10a1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00426751) (`ctg-observation-nct00426751-2012-11-27-74a63272bb20`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00426751." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct00426751-eptifibatide-v1 SHA-256: cfd7a923253e178077f69dea36b1950fc25c142d8943991d40e8668ab4f9caed.

---

<a id="clinicaltrials-gov-nct00638976-eptifibatide-v1"></a>

## ClinicalTrials.gov record NCT00638976

> PeptideScanner retained ClinicalTrials.gov record NCT00638976 at 2026-11-15T21:59:29.646Z. Its registry update date was 2010-05-28, and PeptideScanner's reviewed identity mapping was eptifibatide.

- Evidence object: `story:clinicaltrials-gov-nct00638976-eptifibatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2010-05-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00638976-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct00638976-eptifibatide-v1
- Content SHA-256: `ff85a4fa0d51ce1d5171615857c18e12e254e3e78a417aab4cef694ce5231ee3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00638976 ([`ctg-observation-nct00638976-2010-05-28-b72214da6e98`](#source-ctg-observation-nct00638976-2010-05-28-b72214da6e98))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00638976 at 2026-11-15T21:59:29.646Z. Its registry update date was 2010-05-28, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct00638976-2010-05-28-b72214da6e98`](#source-ctg-observation-nct00638976-2010-05-28-b72214da6e98))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00638976 at 2026-11-15T21:59:29.646Z. Its registry update date was 2010-05-28, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct00638976-2010-05-28-b72214da6e98`](#source-ctg-observation-nct00638976-2010-05-28-b72214da6e98))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00638976-2010-05-28-b72214da6e98`](#source-ctg-observation-nct00638976-2010-05-28-b72214da6e98))

### Sources

<a id="source-ctg-observation-nct00638976-2010-05-28-b72214da6e98"></a>
- **ClinicalTrials.gov record NCT00638976 · retained source version 2010-05-28:b72214da6e98a94c5b551c93fbd16962551834feb30e328b9c3b8199757feb68** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00638976) (`ctg-observation-nct00638976-2010-05-28-b72214da6e98`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00638976." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct00638976-eptifibatide-v1 SHA-256: ff85a4fa0d51ce1d5171615857c18e12e254e3e78a417aab4cef694ce5231ee3.

---

<a id="clinicaltrials-gov-nct00894803-eptifibatide-v1"></a>

## ClinicalTrials.gov record NCT00894803

> PeptideScanner retained ClinicalTrials.gov record NCT00894803 at 2026-11-15T21:59:29.646Z. Its registry update date was 2014-04-17, and PeptideScanner's reviewed identity mapping was eptifibatide.

- Evidence object: `story:clinicaltrials-gov-nct00894803-eptifibatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-04-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00894803-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct00894803-eptifibatide-v1
- Content SHA-256: `1c58e13d428092aa726fec51b6da7784ad791ea3803fb5b53d852f79fba7cb2e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00894803 ([`ctg-observation-nct00894803-2014-04-17-98632f120c03`](#source-ctg-observation-nct00894803-2014-04-17-98632f120c03))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00894803 at 2026-11-15T21:59:29.646Z. Its registry update date was 2014-04-17, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct00894803-2014-04-17-98632f120c03`](#source-ctg-observation-nct00894803-2014-04-17-98632f120c03))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00894803 at 2026-11-15T21:59:29.646Z. Its registry update date was 2014-04-17, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct00894803-2014-04-17-98632f120c03`](#source-ctg-observation-nct00894803-2014-04-17-98632f120c03))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00894803-2014-04-17-98632f120c03`](#source-ctg-observation-nct00894803-2014-04-17-98632f120c03))

### Sources

<a id="source-ctg-observation-nct00894803-2014-04-17-98632f120c03"></a>
- **ClinicalTrials.gov record NCT00894803 · retained source version 2014-04-17:98632f120c037f6b495d4afefa61efd9d0e2a1009d9601ee07d145621af03a16** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00894803) (`ctg-observation-nct00894803-2014-04-17-98632f120c03`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00894803." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct00894803-eptifibatide-v1 SHA-256: 1c58e13d428092aa726fec51b6da7784ad791ea3803fb5b53d852f79fba7cb2e.

---

<a id="clinicaltrials-gov-nct01076764-eptifibatide-v1"></a>

## ClinicalTrials.gov record NCT01076764

> PeptideScanner retained ClinicalTrials.gov record NCT01076764 at 2026-11-15T21:59:29.646Z. Its registry update date was 2016-05-04, and PeptideScanner's reviewed identity mapping was eptifibatide.

- Evidence object: `story:clinicaltrials-gov-nct01076764-eptifibatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-05-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01076764-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct01076764-eptifibatide-v1
- Content SHA-256: `adb97a96ce49a8b9d1d985679612bc4617aab360b5591811cc8787a0b9878c19`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01076764 ([`ctg-observation-nct01076764-2016-05-04-3008f6407baa`](#source-ctg-observation-nct01076764-2016-05-04-3008f6407baa))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01076764 at 2026-11-15T21:59:29.646Z. Its registry update date was 2016-05-04, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct01076764-2016-05-04-3008f6407baa`](#source-ctg-observation-nct01076764-2016-05-04-3008f6407baa))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01076764 at 2026-11-15T21:59:29.646Z. Its registry update date was 2016-05-04, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct01076764-2016-05-04-3008f6407baa`](#source-ctg-observation-nct01076764-2016-05-04-3008f6407baa))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01076764-2016-05-04-3008f6407baa`](#source-ctg-observation-nct01076764-2016-05-04-3008f6407baa))

### Sources

<a id="source-ctg-observation-nct01076764-2016-05-04-3008f6407baa"></a>
- **ClinicalTrials.gov record NCT01076764 · retained source version 2016-05-04:3008f6407baac9d6251057237c18e157ca63515569130eddd650423edfd30b91** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01076764) (`ctg-observation-nct01076764-2016-05-04-3008f6407baa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01076764." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct01076764-eptifibatide-v1 SHA-256: adb97a96ce49a8b9d1d985679612bc4617aab360b5591811cc8787a0b9878c19.

---

<a id="clinicaltrials-gov-nct01103440-eptifibatide-v1"></a>

## ClinicalTrials.gov record NCT01103440

> PeptideScanner retained ClinicalTrials.gov record NCT01103440 at 2026-11-15T21:59:29.646Z. Its registry update date was 2018-02-14, and PeptideScanner's reviewed identity mapping was eptifibatide.

- Evidence object: `story:clinicaltrials-gov-nct01103440-eptifibatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-02-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01103440-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct01103440-eptifibatide-v1
- Content SHA-256: `a9f4632f907b866ce2017a0013c3aff1787ffc056d217a04e13412680b5bc1a1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01103440 ([`ctg-observation-nct01103440-2018-02-14-87db55b802c8`](#source-ctg-observation-nct01103440-2018-02-14-87db55b802c8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01103440 at 2026-11-15T21:59:29.646Z. Its registry update date was 2018-02-14, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct01103440-2018-02-14-87db55b802c8`](#source-ctg-observation-nct01103440-2018-02-14-87db55b802c8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01103440 at 2026-11-15T21:59:29.646Z. Its registry update date was 2018-02-14, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct01103440-2018-02-14-87db55b802c8`](#source-ctg-observation-nct01103440-2018-02-14-87db55b802c8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01103440-2018-02-14-87db55b802c8`](#source-ctg-observation-nct01103440-2018-02-14-87db55b802c8))

### Sources

<a id="source-ctg-observation-nct01103440-2018-02-14-87db55b802c8"></a>
- **ClinicalTrials.gov record NCT01103440 · retained source version 2018-02-14:87db55b802c8c5d36531594429327309d816c30d4e071daec7a6315dc8bfed44** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01103440) (`ctg-observation-nct01103440-2018-02-14-87db55b802c8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01103440." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct01103440-eptifibatide-v1 SHA-256: a9f4632f907b866ce2017a0013c3aff1787ffc056d217a04e13412680b5bc1a1.

---

<a id="clinicaltrials-gov-nct01522417-eptifibatide-v1"></a>

## ClinicalTrials.gov record NCT01522417

> PeptideScanner retained ClinicalTrials.gov record NCT01522417 at 2026-11-15T21:59:29.646Z. Its registry update date was 2021-05-13, and PeptideScanner's reviewed identity mapping was eptifibatide.

- Evidence object: `story:clinicaltrials-gov-nct01522417-eptifibatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-05-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01522417-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct01522417-eptifibatide-v1
- Content SHA-256: `ed86fbbe64c0a5379fc9433b04ab33131271fd09536339cbc834701cf425ac97`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01522417 ([`ctg-observation-nct01522417-2021-05-13-cdcba689503a`](#source-ctg-observation-nct01522417-2021-05-13-cdcba689503a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01522417 at 2026-11-15T21:59:29.646Z. Its registry update date was 2021-05-13, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct01522417-2021-05-13-cdcba689503a`](#source-ctg-observation-nct01522417-2021-05-13-cdcba689503a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01522417 at 2026-11-15T21:59:29.646Z. Its registry update date was 2021-05-13, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct01522417-2021-05-13-cdcba689503a`](#source-ctg-observation-nct01522417-2021-05-13-cdcba689503a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01522417-2021-05-13-cdcba689503a`](#source-ctg-observation-nct01522417-2021-05-13-cdcba689503a))

### Sources

<a id="source-ctg-observation-nct01522417-2021-05-13-cdcba689503a"></a>
- **ClinicalTrials.gov record NCT01522417 · retained source version 2021-05-13:cdcba689503ab5709894aa75468b4e4febc891368664ea0cbf96150181feadb0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01522417) (`ctg-observation-nct01522417-2021-05-13-cdcba689503a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01522417." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct01522417-eptifibatide-v1 SHA-256: ed86fbbe64c0a5379fc9433b04ab33131271fd09536339cbc834701cf425ac97.

---

<a id="clinicaltrials-gov-nct01863134-eptifibatide-v1"></a>

## ClinicalTrials.gov record NCT01863134

> PeptideScanner retained ClinicalTrials.gov record NCT01863134 at 2026-11-15T21:59:29.646Z. Its registry update date was 2013-10-31, and PeptideScanner's reviewed identity mapping was eptifibatide.

- Evidence object: `story:clinicaltrials-gov-nct01863134-eptifibatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-10-31
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01863134-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct01863134-eptifibatide-v1
- Content SHA-256: `83eacab343329f09a7ad37b294ff75348ceaaffea0de2b0d51ef3bd1556800b7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01863134 ([`ctg-observation-nct01863134-2013-10-31-084a4f2a57b4`](#source-ctg-observation-nct01863134-2013-10-31-084a4f2a57b4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01863134 at 2026-11-15T21:59:29.646Z. Its registry update date was 2013-10-31, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct01863134-2013-10-31-084a4f2a57b4`](#source-ctg-observation-nct01863134-2013-10-31-084a4f2a57b4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01863134 at 2026-11-15T21:59:29.646Z. Its registry update date was 2013-10-31, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct01863134-2013-10-31-084a4f2a57b4`](#source-ctg-observation-nct01863134-2013-10-31-084a4f2a57b4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01863134-2013-10-31-084a4f2a57b4`](#source-ctg-observation-nct01863134-2013-10-31-084a4f2a57b4))

### Sources

<a id="source-ctg-observation-nct01863134-2013-10-31-084a4f2a57b4"></a>
- **ClinicalTrials.gov record NCT01863134 · retained source version 2013-10-31:084a4f2a57b4317b467a5f2e26bbdd8c98b05960b2baa6ad0fc1740180b10bd4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01863134) (`ctg-observation-nct01863134-2013-10-31-084a4f2a57b4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01863134." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct01863134-eptifibatide-v1 SHA-256: 83eacab343329f09a7ad37b294ff75348ceaaffea0de2b0d51ef3bd1556800b7.

---

<a id="clinicaltrials-gov-nct01919723-eptifibatide-v1"></a>

## ClinicalTrials.gov record NCT01919723

> PeptideScanner retained ClinicalTrials.gov record NCT01919723 at 2026-11-15T21:59:29.646Z. Its registry update date was 2017-02-28, and PeptideScanner's reviewed identity mapping was eptifibatide.

- Evidence object: `story:clinicaltrials-gov-nct01919723-eptifibatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-02-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01919723-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct01919723-eptifibatide-v1
- Content SHA-256: `a196bf39880521917891f4087b872e60cb25a13dd346710bd3cced7ad7495ff8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01919723 ([`ctg-observation-nct01919723-2017-02-28-51a6080bf7a2`](#source-ctg-observation-nct01919723-2017-02-28-51a6080bf7a2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01919723 at 2026-11-15T21:59:29.646Z. Its registry update date was 2017-02-28, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct01919723-2017-02-28-51a6080bf7a2`](#source-ctg-observation-nct01919723-2017-02-28-51a6080bf7a2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01919723 at 2026-11-15T21:59:29.646Z. Its registry update date was 2017-02-28, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct01919723-2017-02-28-51a6080bf7a2`](#source-ctg-observation-nct01919723-2017-02-28-51a6080bf7a2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01919723-2017-02-28-51a6080bf7a2`](#source-ctg-observation-nct01919723-2017-02-28-51a6080bf7a2))

### Sources

<a id="source-ctg-observation-nct01919723-2017-02-28-51a6080bf7a2"></a>
- **ClinicalTrials.gov record NCT01919723 · retained source version 2017-02-28:51a6080bf7a297968f69115054b3cc2fe3e616f39270b95c6b607bfceab23d43** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01919723) (`ctg-observation-nct01919723-2017-02-28-51a6080bf7a2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01919723." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct01919723-eptifibatide-v1 SHA-256: a196bf39880521917891f4087b872e60cb25a13dd346710bd3cced7ad7495ff8.

---

<a id="clinicaltrials-gov-nct01977456-eptifibatide-v1"></a>

## ClinicalTrials.gov record NCT01977456

> PeptideScanner retained ClinicalTrials.gov record NCT01977456 at 2026-11-15T21:59:29.646Z. Its registry update date was 2016-01-21, and PeptideScanner's reviewed identity mapping was eptifibatide.

- Evidence object: `story:clinicaltrials-gov-nct01977456-eptifibatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-01-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01977456-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct01977456-eptifibatide-v1
- Content SHA-256: `fbe6313600ee2a1b3945e647f45f683fd26a88b48d1e86f36c0f92008db77fb6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01977456 ([`ctg-observation-nct01977456-2016-01-21-ae5bec1b5291`](#source-ctg-observation-nct01977456-2016-01-21-ae5bec1b5291))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01977456 at 2026-11-15T21:59:29.646Z. Its registry update date was 2016-01-21, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct01977456-2016-01-21-ae5bec1b5291`](#source-ctg-observation-nct01977456-2016-01-21-ae5bec1b5291))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01977456 at 2026-11-15T21:59:29.646Z. Its registry update date was 2016-01-21, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct01977456-2016-01-21-ae5bec1b5291`](#source-ctg-observation-nct01977456-2016-01-21-ae5bec1b5291))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01977456-2016-01-21-ae5bec1b5291`](#source-ctg-observation-nct01977456-2016-01-21-ae5bec1b5291))

### Sources

<a id="source-ctg-observation-nct01977456-2016-01-21-ae5bec1b5291"></a>
- **ClinicalTrials.gov record NCT01977456 · retained source version 2016-01-21:ae5bec1b52918778b1c202ceb86579d66b9c252f9ab8d20adb12492774afbdcf** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01977456) (`ctg-observation-nct01977456-2016-01-21-ae5bec1b5291`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01977456." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct01977456-eptifibatide-v1 SHA-256: fbe6313600ee2a1b3945e647f45f683fd26a88b48d1e86f36c0f92008db77fb6.

---

<a id="clinicaltrials-gov-nct02925923-eptifibatide-v1"></a>

## ClinicalTrials.gov record NCT02925923

> PeptideScanner retained ClinicalTrials.gov record NCT02925923 at 2026-11-15T21:59:29.646Z. Its registry update date was 2020-05-04, and PeptideScanner's reviewed identity mapping was eptifibatide.

- Evidence object: `story:clinicaltrials-gov-nct02925923-eptifibatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-05-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02925923-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct02925923-eptifibatide-v1
- Content SHA-256: `b6a567b745cc3c58e8f139150a806f901a32d0fd98cb856d50d5bef47d231d60`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02925923 ([`ctg-observation-nct02925923-2020-05-04-ead5dcef72c6`](#source-ctg-observation-nct02925923-2020-05-04-ead5dcef72c6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02925923 at 2026-11-15T21:59:29.646Z. Its registry update date was 2020-05-04, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct02925923-2020-05-04-ead5dcef72c6`](#source-ctg-observation-nct02925923-2020-05-04-ead5dcef72c6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02925923 at 2026-11-15T21:59:29.646Z. Its registry update date was 2020-05-04, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct02925923-2020-05-04-ead5dcef72c6`](#source-ctg-observation-nct02925923-2020-05-04-ead5dcef72c6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02925923-2020-05-04-ead5dcef72c6`](#source-ctg-observation-nct02925923-2020-05-04-ead5dcef72c6))

### Sources

<a id="source-ctg-observation-nct02925923-2020-05-04-ead5dcef72c6"></a>
- **ClinicalTrials.gov record NCT02925923 · retained source version 2020-05-04:ead5dcef72c654796519dc26ecafd0d7db5c565c255cb05498b0037108b58519** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02925923) (`ctg-observation-nct02925923-2020-05-04-ead5dcef72c6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02925923." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct02925923-eptifibatide-v1 SHA-256: b6a567b745cc3c58e8f139150a806f901a32d0fd98cb856d50d5bef47d231d60.

---

<a id="clinicaltrials-gov-nct03735979-eptifibatide-v1"></a>

## ClinicalTrials.gov record NCT03735979

> PeptideScanner retained ClinicalTrials.gov record NCT03735979 at 2026-11-15T21:59:29.646Z. Its registry update date was 2025-02-07, and PeptideScanner's reviewed identity mapping was eptifibatide.

- Evidence object: `story:clinicaltrials-gov-nct03735979-eptifibatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-02-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03735979-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct03735979-eptifibatide-v1
- Content SHA-256: `918fbc5895c1f769a83fa0dbcc3abd73eeb2e3ad1bfc39b237d3278e980bdfad`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03735979 ([`ctg-observation-nct03735979-2025-02-07-9f5631b092b0`](#source-ctg-observation-nct03735979-2025-02-07-9f5631b092b0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03735979 at 2026-11-15T21:59:29.646Z. Its registry update date was 2025-02-07, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct03735979-2025-02-07-9f5631b092b0`](#source-ctg-observation-nct03735979-2025-02-07-9f5631b092b0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03735979 at 2026-11-15T21:59:29.646Z. Its registry update date was 2025-02-07, and PeptideScanner's reviewed identity mapping was eptifibatide. ([`ctg-observation-nct03735979-2025-02-07-9f5631b092b0`](#source-ctg-observation-nct03735979-2025-02-07-9f5631b092b0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03735979-2025-02-07-9f5631b092b0`](#source-ctg-observation-nct03735979-2025-02-07-9f5631b092b0))

### Sources

<a id="source-ctg-observation-nct03735979-2025-02-07-9f5631b092b0"></a>
- **ClinicalTrials.gov record NCT03735979 · retained source version 2025-02-07:9f5631b092b0b0f25a7ad10eb0560e4f8b47fc1ad6a94ab622b245bc560466f3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03735979) (`ctg-observation-nct03735979-2025-02-07-9f5631b092b0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03735979." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#clinicaltrials-gov-nct03735979-eptifibatide-v1 SHA-256: 918fbc5895c1f769a83fa0dbcc3abd73eeb2e3ad1bfc39b237d3278e980bdfad.

---

<a id="fda-drugs-anda090854-v1"></a>

## Drugs@FDA application ANDA090854

> The official Drugs@FDA dataset lists original submission 1 for ANDA 090854 with status AP dated 2015-06-12, and names eptifibatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda090854:v1`
- Evidence domain: Regulatory
- Date in source: 2015-06-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda090854/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda090854-v1
- Content SHA-256: `abc54686167ff6540dd49773e4aa9c9e32b8d2cffecdd8d61dc59c351103cc96`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA090854 ([`fda-drugs-anda090854-2015-06-12-909e2b87f99e`](#source-fda-drugs-anda090854-2015-06-12-909e2b87f99e))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 090854 with status AP dated 2015-06-12, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda090854-2015-06-12-909e2b87f99e`](#source-fda-drugs-anda090854-2015-06-12-909e2b87f99e))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 090854 with status AP dated 2015-06-12, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda090854-2015-06-12-909e2b87f99e`](#source-fda-drugs-anda090854-2015-06-12-909e2b87f99e))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda090854-2015-06-12-909e2b87f99e`](#source-fda-drugs-anda090854-2015-06-12-909e2b87f99e))

### Sources

<a id="source-fda-drugs-anda090854-2015-06-12-909e2b87f99e"></a>
- **Drugs@FDA application ANDA090854 · original submission status AP · 2015-06-12 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA090854%22&limit=1) (`fda-drugs-anda090854-2015-06-12-909e2b87f99e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA090854." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda090854-v1 SHA-256: abc54686167ff6540dd49773e4aa9c9e32b8d2cffecdd8d61dc59c351103cc96.

---

<a id="fda-drugs-anda091555-v1"></a>

## Drugs@FDA application ANDA091555

> The official Drugs@FDA dataset lists original submission 1 for ANDA 091555 with status AP dated 2015-06-05, and names eptifibatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda091555:v1`
- Evidence domain: Regulatory
- Date in source: 2015-06-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda091555/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda091555-v1
- Content SHA-256: `01df2a0190c3125f9c4c6ed95947e394f8d90fb25009d25fee61bfe438ff3d95`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA091555 ([`fda-drugs-anda091555-2015-06-05-ddc4a28ac1bd`](#source-fda-drugs-anda091555-2015-06-05-ddc4a28ac1bd))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 091555 with status AP dated 2015-06-05, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda091555-2015-06-05-ddc4a28ac1bd`](#source-fda-drugs-anda091555-2015-06-05-ddc4a28ac1bd))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 091555 with status AP dated 2015-06-05, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda091555-2015-06-05-ddc4a28ac1bd`](#source-fda-drugs-anda091555-2015-06-05-ddc4a28ac1bd))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda091555-2015-06-05-ddc4a28ac1bd`](#source-fda-drugs-anda091555-2015-06-05-ddc4a28ac1bd))

### Sources

<a id="source-fda-drugs-anda091555-2015-06-05-ddc4a28ac1bd"></a>
- **Drugs@FDA application ANDA091555 · original submission status AP · 2015-06-05 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA091555%22&limit=1) (`fda-drugs-anda091555-2015-06-05-ddc4a28ac1bd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA091555." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda091555-v1 SHA-256: 01df2a0190c3125f9c4c6ed95947e394f8d90fb25009d25fee61bfe438ff3d95.

---

<a id="fda-drugs-anda203258-v1"></a>

## Drugs@FDA application ANDA203258

> The official Drugs@FDA dataset lists original submission 1 for ANDA 203258 with status AP dated 2018-07-20, and names eptifibatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda203258:v1`
- Evidence domain: Regulatory
- Date in source: 2018-07-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda203258/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda203258-v1
- Content SHA-256: `b1f16d88c7edf806ba81709d21595b215c9a133307c2aef803dc1c646b765ac4`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA203258 ([`fda-drugs-anda203258-2018-07-20-ea9cac836021`](#source-fda-drugs-anda203258-2018-07-20-ea9cac836021))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 203258 with status AP dated 2018-07-20, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda203258-2018-07-20-ea9cac836021`](#source-fda-drugs-anda203258-2018-07-20-ea9cac836021))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 203258 with status AP dated 2018-07-20, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda203258-2018-07-20-ea9cac836021`](#source-fda-drugs-anda203258-2018-07-20-ea9cac836021))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda203258-2018-07-20-ea9cac836021`](#source-fda-drugs-anda203258-2018-07-20-ea9cac836021))

### Sources

<a id="source-fda-drugs-anda203258-2018-07-20-ea9cac836021"></a>
- **Drugs@FDA application ANDA203258 · original submission status AP · 2018-07-20 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA203258%22&limit=1) (`fda-drugs-anda203258-2018-07-20-ea9cac836021`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA203258." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda203258-v1 SHA-256: b1f16d88c7edf806ba81709d21595b215c9a133307c2aef803dc1c646b765ac4.

---

<a id="fda-drugs-anda204361-v1"></a>

## Drugs@FDA application ANDA204361

> The official Drugs@FDA dataset lists original submission 1 for ANDA 204361 with status AP dated 2019-03-14, and names eptifibatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda204361:v1`
- Evidence domain: Regulatory
- Date in source: 2019-03-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda204361/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda204361-v1
- Content SHA-256: `e68c2cb1333dd55883b61cdf9c2b68eda66b9818ac4b3068a6ed8b204a61d7bb`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA204361 ([`fda-drugs-anda204361-2019-03-14-1ea1c1928903`](#source-fda-drugs-anda204361-2019-03-14-1ea1c1928903))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 204361 with status AP dated 2019-03-14, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda204361-2019-03-14-1ea1c1928903`](#source-fda-drugs-anda204361-2019-03-14-1ea1c1928903))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 204361 with status AP dated 2019-03-14, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda204361-2019-03-14-1ea1c1928903`](#source-fda-drugs-anda204361-2019-03-14-1ea1c1928903))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda204361-2019-03-14-1ea1c1928903`](#source-fda-drugs-anda204361-2019-03-14-1ea1c1928903))

### Sources

<a id="source-fda-drugs-anda204361-2019-03-14-1ea1c1928903"></a>
- **Drugs@FDA application ANDA204361 · original submission status AP · 2019-03-14 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA204361%22&limit=1) (`fda-drugs-anda204361-2019-03-14-1ea1c1928903`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA204361." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda204361-v1 SHA-256: e68c2cb1333dd55883b61cdf9c2b68eda66b9818ac4b3068a6ed8b204a61d7bb.

---

<a id="fda-drugs-anda204362-v1"></a>

## Drugs@FDA application ANDA204362

> The official Drugs@FDA dataset lists original submission 1 for ANDA 204362 with status AP dated 2019-03-11, and names eptifibatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda204362:v1`
- Evidence domain: Regulatory
- Date in source: 2019-03-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda204362/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda204362-v1
- Content SHA-256: `1f662a4affe6a7df326140a069c41641b93f91e6a85be21db2e631d74e6f331d`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA204362 ([`fda-drugs-anda204362-2019-03-11-f92e62687e30`](#source-fda-drugs-anda204362-2019-03-11-f92e62687e30))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 204362 with status AP dated 2019-03-11, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda204362-2019-03-11-f92e62687e30`](#source-fda-drugs-anda204362-2019-03-11-f92e62687e30))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 204362 with status AP dated 2019-03-11, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda204362-2019-03-11-f92e62687e30`](#source-fda-drugs-anda204362-2019-03-11-f92e62687e30))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda204362-2019-03-11-f92e62687e30`](#source-fda-drugs-anda204362-2019-03-11-f92e62687e30))

### Sources

<a id="source-fda-drugs-anda204362-2019-03-11-f92e62687e30"></a>
- **Drugs@FDA application ANDA204362 · original submission status AP · 2019-03-11 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA204362%22&limit=1) (`fda-drugs-anda204362-2019-03-11-f92e62687e30`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA204362." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda204362-v1 SHA-256: 1f662a4affe6a7df326140a069c41641b93f91e6a85be21db2e631d74e6f331d.

---

<a id="fda-drugs-anda204589-v1"></a>

## Drugs@FDA application ANDA204589

> The official Drugs@FDA dataset lists original submission 1 for ANDA 204589 with status AP dated 2017-04-18, and names eptifibatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda204589:v1`
- Evidence domain: Regulatory
- Date in source: 2017-04-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda204589/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda204589-v1
- Content SHA-256: `c8e8b9c292bc308a1fda4fb21c2b6c8848fbfaa44ca6cb96fa9c8bc6767af4e2`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA204589 ([`fda-drugs-anda204589-2017-04-18-c2d814aa11f5`](#source-fda-drugs-anda204589-2017-04-18-c2d814aa11f5))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 204589 with status AP dated 2017-04-18, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda204589-2017-04-18-c2d814aa11f5`](#source-fda-drugs-anda204589-2017-04-18-c2d814aa11f5))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 204589 with status AP dated 2017-04-18, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda204589-2017-04-18-c2d814aa11f5`](#source-fda-drugs-anda204589-2017-04-18-c2d814aa11f5))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda204589-2017-04-18-c2d814aa11f5`](#source-fda-drugs-anda204589-2017-04-18-c2d814aa11f5))

### Sources

<a id="source-fda-drugs-anda204589-2017-04-18-c2d814aa11f5"></a>
- **Drugs@FDA application ANDA204589 · original submission status AP · 2017-04-18 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA204589%22&limit=1) (`fda-drugs-anda204589-2017-04-18-c2d814aa11f5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA204589." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda204589-v1 SHA-256: c8e8b9c292bc308a1fda4fb21c2b6c8848fbfaa44ca6cb96fa9c8bc6767af4e2.

---

<a id="fda-drugs-anda204693-v1"></a>

## Drugs@FDA application ANDA204693

> The official Drugs@FDA dataset lists original submission 1 for ANDA 204693 with status AP dated 2018-03-07, and names eptifibatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda204693:v1`
- Evidence domain: Regulatory
- Date in source: 2018-03-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda204693/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda204693-v1
- Content SHA-256: `b3e993ec63be2cb73406efda631e843e1b3fa0c6f7ff99675b11f1aceb966cee`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA204693 ([`fda-drugs-anda204693-2018-03-07-d3e61edad63f`](#source-fda-drugs-anda204693-2018-03-07-d3e61edad63f))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 204693 with status AP dated 2018-03-07, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda204693-2018-03-07-d3e61edad63f`](#source-fda-drugs-anda204693-2018-03-07-d3e61edad63f))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 204693 with status AP dated 2018-03-07, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda204693-2018-03-07-d3e61edad63f`](#source-fda-drugs-anda204693-2018-03-07-d3e61edad63f))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda204693-2018-03-07-d3e61edad63f`](#source-fda-drugs-anda204693-2018-03-07-d3e61edad63f))

### Sources

<a id="source-fda-drugs-anda204693-2018-03-07-d3e61edad63f"></a>
- **Drugs@FDA application ANDA204693 · original submission status AP · 2018-03-07 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA204693%22&limit=1) (`fda-drugs-anda204693-2018-03-07-d3e61edad63f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA204693." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda204693-v1 SHA-256: b3e993ec63be2cb73406efda631e843e1b3fa0c6f7ff99675b11f1aceb966cee.

---

<a id="fda-drugs-anda205557-v1"></a>

## Drugs@FDA application ANDA205557

> The official Drugs@FDA dataset lists original submission 1 for ANDA 205557 with status AP dated 2017-11-06, and names eptifibatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda205557:v1`
- Evidence domain: Regulatory
- Date in source: 2017-11-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda205557/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda205557-v1
- Content SHA-256: `c6c81cdc4c5c03eb5360319f36d68f82c4aa0a5fa817f621926730cef49664cb`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA205557 ([`fda-drugs-anda205557-2017-11-06-c458e6fbb27f`](#source-fda-drugs-anda205557-2017-11-06-c458e6fbb27f))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 205557 with status AP dated 2017-11-06, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda205557-2017-11-06-c458e6fbb27f`](#source-fda-drugs-anda205557-2017-11-06-c458e6fbb27f))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 205557 with status AP dated 2017-11-06, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda205557-2017-11-06-c458e6fbb27f`](#source-fda-drugs-anda205557-2017-11-06-c458e6fbb27f))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda205557-2017-11-06-c458e6fbb27f`](#source-fda-drugs-anda205557-2017-11-06-c458e6fbb27f))

### Sources

<a id="source-fda-drugs-anda205557-2017-11-06-c458e6fbb27f"></a>
- **Drugs@FDA application ANDA205557 · original submission status AP · 2017-11-06 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA205557%22&limit=1) (`fda-drugs-anda205557-2017-11-06-c458e6fbb27f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA205557." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda205557-v1 SHA-256: c6c81cdc4c5c03eb5360319f36d68f82c4aa0a5fa817f621926730cef49664cb.

---

<a id="fda-drugs-anda206127-v1"></a>

## Drugs@FDA application ANDA206127

> The official Drugs@FDA dataset lists original submission 1 for ANDA 206127 with status AP dated 2015-12-08, and names eptifibatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda206127:v1`
- Evidence domain: Regulatory
- Date in source: 2015-12-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda206127/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda206127-v1
- Content SHA-256: `730ecdc4d271c42fd04ae91d6bcc77e6333061e46be4da59f613aa4b2fd61c55`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA206127 ([`fda-drugs-anda206127-2015-12-08-2f6c28fcda54`](#source-fda-drugs-anda206127-2015-12-08-2f6c28fcda54))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 206127 with status AP dated 2015-12-08, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda206127-2015-12-08-2f6c28fcda54`](#source-fda-drugs-anda206127-2015-12-08-2f6c28fcda54))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 206127 with status AP dated 2015-12-08, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda206127-2015-12-08-2f6c28fcda54`](#source-fda-drugs-anda206127-2015-12-08-2f6c28fcda54))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda206127-2015-12-08-2f6c28fcda54`](#source-fda-drugs-anda206127-2015-12-08-2f6c28fcda54))

### Sources

<a id="source-fda-drugs-anda206127-2015-12-08-2f6c28fcda54"></a>
- **Drugs@FDA application ANDA206127 · original submission status AP · 2015-12-08 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA206127%22&limit=1) (`fda-drugs-anda206127-2015-12-08-2f6c28fcda54`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA206127." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda206127-v1 SHA-256: 730ecdc4d271c42fd04ae91d6bcc77e6333061e46be4da59f613aa4b2fd61c55.

---

<a id="fda-drugs-anda207864-v1"></a>

## Drugs@FDA application ANDA207864

> The official Drugs@FDA dataset lists original submission 1 for ANDA 207864 with status AP dated 2020-03-20, and names eptifibatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda207864:v1`
- Evidence domain: Regulatory
- Date in source: 2020-03-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda207864/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda207864-v1
- Content SHA-256: `9377d57167ecdc4d00ed4597aad76e2ebccae585478918a675107671cc59287d`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA207864 ([`fda-drugs-anda207864-2020-03-20-caac73805f63`](#source-fda-drugs-anda207864-2020-03-20-caac73805f63))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 207864 with status AP dated 2020-03-20, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda207864-2020-03-20-caac73805f63`](#source-fda-drugs-anda207864-2020-03-20-caac73805f63))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 207864 with status AP dated 2020-03-20, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda207864-2020-03-20-caac73805f63`](#source-fda-drugs-anda207864-2020-03-20-caac73805f63))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda207864-2020-03-20-caac73805f63`](#source-fda-drugs-anda207864-2020-03-20-caac73805f63))

### Sources

<a id="source-fda-drugs-anda207864-2020-03-20-caac73805f63"></a>
- **Drugs@FDA application ANDA207864 · original submission status AP · 2020-03-20 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA207864%22&limit=1) (`fda-drugs-anda207864-2020-03-20-caac73805f63`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA207864." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda207864-v1 SHA-256: 9377d57167ecdc4d00ed4597aad76e2ebccae585478918a675107671cc59287d.

---

<a id="fda-drugs-anda208554-v1"></a>

## Drugs@FDA application ANDA208554

> The official Drugs@FDA dataset lists original submission 1 for ANDA 208554 with status AP dated 2018-11-23, and names eptifibatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda208554:v1`
- Evidence domain: Regulatory
- Date in source: 2018-11-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda208554/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda208554-v1
- Content SHA-256: `ccae29e5734ad2db1502002ea42faa991dda9d499d85f6e12ba8660f09a2c151`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA208554 ([`fda-drugs-anda208554-2018-11-23-608a113fe201`](#source-fda-drugs-anda208554-2018-11-23-608a113fe201))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 208554 with status AP dated 2018-11-23, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda208554-2018-11-23-608a113fe201`](#source-fda-drugs-anda208554-2018-11-23-608a113fe201))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 208554 with status AP dated 2018-11-23, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda208554-2018-11-23-608a113fe201`](#source-fda-drugs-anda208554-2018-11-23-608a113fe201))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda208554-2018-11-23-608a113fe201`](#source-fda-drugs-anda208554-2018-11-23-608a113fe201))

### Sources

<a id="source-fda-drugs-anda208554-2018-11-23-608a113fe201"></a>
- **Drugs@FDA application ANDA208554 · original submission status AP · 2018-11-23 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA208554%22&limit=1) (`fda-drugs-anda208554-2018-11-23-608a113fe201`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA208554." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda208554-v1 SHA-256: ccae29e5734ad2db1502002ea42faa991dda9d499d85f6e12ba8660f09a2c151.

---

<a id="fda-drugs-anda209864-v1"></a>

## Drugs@FDA application ANDA209864

> The official Drugs@FDA dataset lists original submission 1 for ANDA 209864 with status AP dated 2019-01-25, and names eptifibatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda209864:v1`
- Evidence domain: Regulatory
- Date in source: 2019-01-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda209864/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda209864-v1
- Content SHA-256: `cf6aeb48918065e333c74618cde108a0755119898b5dfc1dd452ab12d0e6eb09`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA209864 ([`fda-drugs-anda209864-2019-01-25-03cbd02c30ff`](#source-fda-drugs-anda209864-2019-01-25-03cbd02c30ff))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 209864 with status AP dated 2019-01-25, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda209864-2019-01-25-03cbd02c30ff`](#source-fda-drugs-anda209864-2019-01-25-03cbd02c30ff))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 209864 with status AP dated 2019-01-25, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda209864-2019-01-25-03cbd02c30ff`](#source-fda-drugs-anda209864-2019-01-25-03cbd02c30ff))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda209864-2019-01-25-03cbd02c30ff`](#source-fda-drugs-anda209864-2019-01-25-03cbd02c30ff))

### Sources

<a id="source-fda-drugs-anda209864-2019-01-25-03cbd02c30ff"></a>
- **Drugs@FDA application ANDA209864 · original submission status AP · 2019-01-25 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA209864%22&limit=1) (`fda-drugs-anda209864-2019-01-25-03cbd02c30ff`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA209864." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda209864-v1 SHA-256: cf6aeb48918065e333c74618cde108a0755119898b5dfc1dd452ab12d0e6eb09.

---

<a id="fda-drugs-anda213081-v1"></a>

## Drugs@FDA application ANDA213081

> The official Drugs@FDA dataset lists original submission 1 for ANDA 213081 with status AP dated 2021-09-07, and names eptifibatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda213081:v1`
- Evidence domain: Regulatory
- Date in source: 2021-09-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda213081/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda213081-v1
- Content SHA-256: `b5cb4724b0a58dcd1d12c1c3374f259de1732f527438e040f3ad68a518effece`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA213081 ([`fda-drugs-anda213081-2021-09-07-296566c31073`](#source-fda-drugs-anda213081-2021-09-07-296566c31073))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 213081 with status AP dated 2021-09-07, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda213081-2021-09-07-296566c31073`](#source-fda-drugs-anda213081-2021-09-07-296566c31073))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 213081 with status AP dated 2021-09-07, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda213081-2021-09-07-296566c31073`](#source-fda-drugs-anda213081-2021-09-07-296566c31073))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda213081-2021-09-07-296566c31073`](#source-fda-drugs-anda213081-2021-09-07-296566c31073))

### Sources

<a id="source-fda-drugs-anda213081-2021-09-07-296566c31073"></a>
- **Drugs@FDA application ANDA213081 · original submission status AP · 2021-09-07 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA213081%22&limit=1) (`fda-drugs-anda213081-2021-09-07-296566c31073`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA213081." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda213081-v1 SHA-256: b5cb4724b0a58dcd1d12c1c3374f259de1732f527438e040f3ad68a518effece.

---

<a id="fda-drugs-anda213599-v1"></a>

## Drugs@FDA application ANDA213599

> The official Drugs@FDA dataset lists original submission 1 for ANDA 213599 with status AP dated 2024-05-09, and names eptifibatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda213599:v1`
- Evidence domain: Regulatory
- Date in source: 2024-05-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda213599/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda213599-v1
- Content SHA-256: `d0dc72e549322198a4f1881f561f3bc85ce3fad35b56166d7b7b3101d3d06113`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA213599 ([`fda-drugs-anda213599-2024-05-09-c5c4d6b47b82`](#source-fda-drugs-anda213599-2024-05-09-c5c4d6b47b82))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 213599 with status AP dated 2024-05-09, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda213599-2024-05-09-c5c4d6b47b82`](#source-fda-drugs-anda213599-2024-05-09-c5c4d6b47b82))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 213599 with status AP dated 2024-05-09, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-anda213599-2024-05-09-c5c4d6b47b82`](#source-fda-drugs-anda213599-2024-05-09-c5c4d6b47b82))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda213599-2024-05-09-c5c4d6b47b82`](#source-fda-drugs-anda213599-2024-05-09-c5c4d6b47b82))

### Sources

<a id="source-fda-drugs-anda213599-2024-05-09-c5c4d6b47b82"></a>
- **Drugs@FDA application ANDA213599 · original submission status AP · 2024-05-09 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA213599%22&limit=1) (`fda-drugs-anda213599-2024-05-09-c5c4d6b47b82`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA213599." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-anda213599-v1 SHA-256: d0dc72e549322198a4f1881f561f3bc85ce3fad35b56166d7b7b3101d3d06113.

---

<a id="fda-drugs-nda020718-v1"></a>

## Drugs@FDA application NDA020718

> The official Drugs@FDA dataset lists original submission 1 for NDA 020718 with status AP dated 1998-05-18, and names eptifibatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda020718:v1`
- Evidence domain: Regulatory
- Date in source: 1998-05-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda020718/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-nda020718-v1
- Content SHA-256: `8f637ea6d7fa5e5a3cf958afff78cbb50cfb49877a43e6a295e373b66f14e302`

### Claims and source pins

#### Headline

Drugs@FDA application NDA020718 ([`fda-drugs-nda020718-1998-05-18-05efefeb337c`](#source-fda-drugs-nda020718-1998-05-18-05efefeb337c))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 020718 with status AP dated 1998-05-18, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-nda020718-1998-05-18-05efefeb337c`](#source-fda-drugs-nda020718-1998-05-18-05efefeb337c))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 020718 with status AP dated 1998-05-18, and names eptifibatide among the application record's active ingredients. ([`fda-drugs-nda020718-1998-05-18-05efefeb337c`](#source-fda-drugs-nda020718-1998-05-18-05efefeb337c))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda020718-1998-05-18-05efefeb337c`](#source-fda-drugs-nda020718-1998-05-18-05efefeb337c))

### Sources

<a id="source-fda-drugs-nda020718-1998-05-18-05efefeb337c"></a>
- **Drugs@FDA application NDA020718 · original submission status AP · 1998-05-18 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA020718%22&limit=1) (`fda-drugs-nda020718-1998-05-18-05efefeb337c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA020718." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#fda-drugs-nda020718-v1 SHA-256: 8f637ea6d7fa5e5a3cf958afff78cbb50cfb49877a43e6a295e373b66f14e302.

---

<a id="federal-register-2021-16047-v1"></a>

## Federal Register notice 2021-16047

> The Federal Register published notice 2021-16047, attributed to FDA and its parent HHS department, on 2021-07-28. Its official title is “Fresenius Kabi USA, LLC, et al.; Withdrawal of Approval of 15 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Eptifibatide.

- Evidence object: `story:federal-register-2021-16047:v1`
- Evidence domain: Regulatory
- Date in source: 2021-07-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2021-16047/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#federal-register-2021-16047-v1
- Content SHA-256: `e0942e325295800e49a6a9210b2615a44b1dc40a029869f6c9a0b0a91b34b86b`

### Claims and source pins

#### Headline

Federal Register notice 2021-16047 ([`federal-register-2021-16047-57d6beb5455c`](#source-federal-register-2021-16047-57d6beb5455c))

#### Summary

The Federal Register published notice 2021-16047, attributed to FDA and its parent HHS department, on 2021-07-28. Its official title is “Fresenius Kabi USA, LLC, et al.; Withdrawal of Approval of 15 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Eptifibatide. ([`federal-register-2021-16047-57d6beb5455c`](#source-federal-register-2021-16047-57d6beb5455c))

#### Paragraph 1

The Federal Register published notice 2021-16047, attributed to FDA and its parent HHS department, on 2021-07-28. Its official title is “Fresenius Kabi USA, LLC, et al.; Withdrawal of Approval of 15 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Eptifibatide. ([`federal-register-2021-16047-57d6beb5455c`](#source-federal-register-2021-16047-57d6beb5455c))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2021-16047-57d6beb5455c`](#source-federal-register-2021-16047-57d6beb5455c))

### Sources

<a id="source-federal-register-2021-16047-57d6beb5455c"></a>
- **Federal Register notice 2021-16047 · published 2021-07-28 · Fresenius Kabi USA, LLC, et al.; Withdrawal of Approval of 15 Abbreviated New Drug Applications** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2021-07-28/pdf/2021-16047.pdf) (`federal-register-2021-16047-57d6beb5455c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2021-16047." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#federal-register-2021-16047-v1 SHA-256: e0942e325295800e49a6a9210b2615a44b1dc40a029869f6c9a0b0a91b34b86b.

---

<a id="federal-register-2022-17056-v1"></a>

## Federal Register notice 2022-17056

> The Federal Register published notice 2022-17056, attributed to FDA and its parent HHS department, on 2022-08-09. Its official title is “Determination That AVC (Sulfanilamide) Vaginal Cream, 15%, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Eptifibatide.

- Evidence object: `story:federal-register-2022-17056:v1`
- Evidence domain: Regulatory
- Date in source: 2022-08-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2022-17056/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#federal-register-2022-17056-v1
- Content SHA-256: `95cb8c334102e58d9e1d673e473eef202fe01f538f49c32ca322832db0649c36`

### Claims and source pins

#### Headline

Federal Register notice 2022-17056 ([`federal-register-2022-17056-3ab5fa8e92ba`](#source-federal-register-2022-17056-3ab5fa8e92ba))

#### Summary

The Federal Register published notice 2022-17056, attributed to FDA and its parent HHS department, on 2022-08-09. Its official title is “Determination That AVC (Sulfanilamide) Vaginal Cream, 15%, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Eptifibatide. ([`federal-register-2022-17056-3ab5fa8e92ba`](#source-federal-register-2022-17056-3ab5fa8e92ba))

#### Paragraph 1

The Federal Register published notice 2022-17056, attributed to FDA and its parent HHS department, on 2022-08-09. Its official title is “Determination That AVC (Sulfanilamide) Vaginal Cream, 15%, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Eptifibatide. ([`federal-register-2022-17056-3ab5fa8e92ba`](#source-federal-register-2022-17056-3ab5fa8e92ba))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2022-17056-3ab5fa8e92ba`](#source-federal-register-2022-17056-3ab5fa8e92ba))

### Sources

<a id="source-federal-register-2022-17056-3ab5fa8e92ba"></a>
- **Federal Register notice 2022-17056 · published 2022-08-09 · Determination That AVC (Sulfanilamide) Vaginal Cream, 15%, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2022-08-09/pdf/2022-17056.pdf) (`federal-register-2022-17056-3ab5fa8e92ba`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2022-17056." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#federal-register-2022-17056-v1 SHA-256: 95cb8c334102e58d9e1d673e473eef202fe01f538f49c32ca322832db0649c36.

---

<a id="federal-register-97-32874-v1"></a>

## Federal Register notice 97-32874

> The Federal Register published notice 97-32874, attributed to FDA and its parent HHS department, on 1997-12-17. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Eptifibatide.

- Evidence object: `story:federal-register-97-32874:v1`
- Evidence domain: Regulatory
- Date in source: 1997-12-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-97-32874/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#federal-register-97-32874-v1
- Content SHA-256: `2e681a27200b6462094ed146d77b595a70e15c186e20bcce9ee10291304cba73`

### Claims and source pins

#### Headline

Federal Register notice 97-32874 ([`federal-register-97-32874-48a18c4f89e6`](#source-federal-register-97-32874-48a18c4f89e6))

#### Summary

The Federal Register published notice 97-32874, attributed to FDA and its parent HHS department, on 1997-12-17. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Eptifibatide. ([`federal-register-97-32874-48a18c4f89e6`](#source-federal-register-97-32874-48a18c4f89e6))

#### Paragraph 1

The Federal Register published notice 97-32874, attributed to FDA and its parent HHS department, on 1997-12-17. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Eptifibatide. ([`federal-register-97-32874-48a18c4f89e6`](#source-federal-register-97-32874-48a18c4f89e6))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-97-32874-48a18c4f89e6`](#source-federal-register-97-32874-48a18c4f89e6))

### Sources

<a id="source-federal-register-97-32874-48a18c4f89e6"></a>
- **Federal Register notice 97-32874 · published 1997-12-17 · Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-1997-12-17/pdf/97-32874.pdf) (`federal-register-97-32874-48a18c4f89e6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 97-32874." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#federal-register-97-32874-v1 SHA-256: 2e681a27200b6462094ed146d77b595a70e15c186e20bcce9ee10291304cba73.

---

<a id="pubmed-pmid-12462900-eptifibatide-v1"></a>

## \[Value of eptifibatide during salvage angioplasty with coronary stenting after failure of thrombolysis. Report of a series of 41 patients\].

> PubMed lists PMID 12462900 in Archives des maladies du coeur et des vaisseaux as Clinical Trial, Journal Article, with publication-date metadata of 2002-10 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-12462900-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-12462900-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-12462900-eptifibatide-v1
- Content SHA-256: `60365279b3c0f6f316ba1d5128689c9362430f9639e62d53d5e30a0a9311a0c1`

### Claims and source pins

#### Headline

\[Value of eptifibatide during salvage angioplasty with coronary stenting after failure of thrombolysis. Report of a series of 41 patients\]. ([`pubmed-observation-pmid-12462900-2018-11-30-109c5823e46f`](#source-pubmed-observation-pmid-12462900-2018-11-30-109c5823e46f))

#### Summary

PubMed lists PMID 12462900 in Archives des maladies du coeur et des vaisseaux as Clinical Trial, Journal Article, with publication-date metadata of 2002-10 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12462900-2018-11-30-109c5823e46f`](#source-pubmed-observation-pmid-12462900-2018-11-30-109c5823e46f))

#### Paragraph 1

PubMed lists PMID 12462900 in Archives des maladies du coeur et des vaisseaux as Clinical Trial, Journal Article, with publication-date metadata of 2002-10 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12462900-2018-11-30-109c5823e46f`](#source-pubmed-observation-pmid-12462900-2018-11-30-109c5823e46f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-12462900-2018-11-30-109c5823e46f`](#source-pubmed-observation-pmid-12462900-2018-11-30-109c5823e46f))

### Sources

<a id="source-pubmed-observation-pmid-12462900-2018-11-30-109c5823e46f"></a>
- **\[Value of eptifibatide during salvage angioplasty with coronary stenting after failure of thrombolysis. Report of a series of 41 patients\]. · retained source version 1:2018-11-30:current:109c5823e46fb8bcc406d1548f1d6bc368158ae7758580ce52d29e3cc63684e5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/12462900/) (`pubmed-observation-pmid-12462900-2018-11-30-109c5823e46f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Value of eptifibatide during salvage angioplasty with coronary stenting after failure of thrombolysis. Report of a series of 41 patients\]." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-12462900-eptifibatide-v1 SHA-256: 60365279b3c0f6f316ba1d5128689c9362430f9639e62d53d5e30a0a9311a0c1.

---

<a id="pubmed-pmid-15110131-eptifibatide-v1"></a>

## Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function.

> PubMed lists PMID 15110131 in Clinical therapeutics as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 2004-03 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15110131-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-09-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15110131-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-15110131-eptifibatide-v1
- Content SHA-256: `34a9acd3ed6a927e732fa919ed3b2532eedb058e28370ac87fbc6e43d030be3a`

### Claims and source pins

#### Headline

Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. ([`pubmed-observation-pmid-15110131-2019-09-22-c1e0f2c0c4a4`](#source-pubmed-observation-pmid-15110131-2019-09-22-c1e0f2c0c4a4))

#### Summary

PubMed lists PMID 15110131 in Clinical therapeutics as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 2004-03 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15110131-2019-09-22-c1e0f2c0c4a4`](#source-pubmed-observation-pmid-15110131-2019-09-22-c1e0f2c0c4a4))

#### Paragraph 1

PubMed lists PMID 15110131 in Clinical therapeutics as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 2004-03 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15110131-2019-09-22-c1e0f2c0c4a4`](#source-pubmed-observation-pmid-15110131-2019-09-22-c1e0f2c0c4a4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15110131-2019-09-22-c1e0f2c0c4a4`](#source-pubmed-observation-pmid-15110131-2019-09-22-c1e0f2c0c4a4))

### Sources

<a id="source-pubmed-observation-pmid-15110131-2019-09-22-c1e0f2c0c4a4"></a>
- **Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. · retained source version 1:2019-09-22:current:c1e0f2c0c4a4436ae2e3e160a4d14ffb49f94ce89b525efef3515177b2117403** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15110131/) (`pubmed-observation-pmid-15110131-2019-09-22-c1e0f2c0c4a4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-15110131-eptifibatide-v1 SHA-256: 34a9acd3ed6a927e732fa919ed3b2532eedb058e28370ac87fbc6e43d030be3a.

---

<a id="pubmed-pmid-17489665-eptifibatide-v1"></a>

## Present and evolving role of eptifibatide in the treatment of acute coronary syndromes.

> PubMed lists PMID 17489665 in Expert review of cardiovascular therapy as Journal Article, Review, with publication-date metadata of 2007-05 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17489665-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17489665-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-17489665-eptifibatide-v1
- Content SHA-256: `9c4847b207b26f719d14762de09c3c2ecda790297d3535676f594d8a136bf8f9`

### Claims and source pins

#### Headline

Present and evolving role of eptifibatide in the treatment of acute coronary syndromes. ([`pubmed-observation-pmid-17489665-2018-12-01-a175d7e65120`](#source-pubmed-observation-pmid-17489665-2018-12-01-a175d7e65120))

#### Summary

PubMed lists PMID 17489665 in Expert review of cardiovascular therapy as Journal Article, Review, with publication-date metadata of 2007-05 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17489665-2018-12-01-a175d7e65120`](#source-pubmed-observation-pmid-17489665-2018-12-01-a175d7e65120))

#### Paragraph 1

PubMed lists PMID 17489665 in Expert review of cardiovascular therapy as Journal Article, Review, with publication-date metadata of 2007-05 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17489665-2018-12-01-a175d7e65120`](#source-pubmed-observation-pmid-17489665-2018-12-01-a175d7e65120))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17489665-2018-12-01-a175d7e65120`](#source-pubmed-observation-pmid-17489665-2018-12-01-a175d7e65120))

### Sources

<a id="source-pubmed-observation-pmid-17489665-2018-12-01-a175d7e65120"></a>
- **Present and evolving role of eptifibatide in the treatment of acute coronary syndromes. · retained source version 1:2018-12-01:current:a175d7e651205707710625af3476e6abed8636a736afa9ebfda6463473f4da5a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17489665/) (`pubmed-observation-pmid-17489665-2018-12-01-a175d7e65120`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Present and evolving role of eptifibatide in the treatment of acute coronary syndromes." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-17489665-eptifibatide-v1 SHA-256: 9c4847b207b26f719d14762de09c3c2ecda790297d3535676f594d8a136bf8f9.

---

<a id="pubmed-pmid-17916103-eptifibatide-v1"></a>

## Phase I study of eptifibatide in patients with sickle cell anaemia.

> PubMed lists PMID 17916103 in British journal of haematology as Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-10-03 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17916103-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17916103-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-17916103-eptifibatide-v1
- Content SHA-256: `3640fcbfb7d98fbb86e867875e77e902ae420ac1746a3a2f33f00aae07d208d8`

### Claims and source pins

#### Headline

Phase I study of eptifibatide in patients with sickle cell anaemia. ([`pubmed-observation-pmid-17916103-2018-12-01-ff1ce28ff3a3`](#source-pubmed-observation-pmid-17916103-2018-12-01-ff1ce28ff3a3))

#### Summary

PubMed lists PMID 17916103 in British journal of haematology as Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-10-03 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17916103-2018-12-01-ff1ce28ff3a3`](#source-pubmed-observation-pmid-17916103-2018-12-01-ff1ce28ff3a3))

#### Paragraph 1

PubMed lists PMID 17916103 in British journal of haematology as Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-10-03 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17916103-2018-12-01-ff1ce28ff3a3`](#source-pubmed-observation-pmid-17916103-2018-12-01-ff1ce28ff3a3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17916103-2018-12-01-ff1ce28ff3a3`](#source-pubmed-observation-pmid-17916103-2018-12-01-ff1ce28ff3a3))

### Sources

<a id="source-pubmed-observation-pmid-17916103-2018-12-01-ff1ce28ff3a3"></a>
- **Phase I study of eptifibatide in patients with sickle cell anaemia. · retained source version 1:2018-12-01:current:ff1ce28ff3a39bb1aa4b9524ece3ec936f2a04d23301f28d69c3b5cdb82bc16e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17916103/) (`pubmed-observation-pmid-17916103-2018-12-01-ff1ce28ff3a3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Phase I study of eptifibatide in patients with sickle cell anaemia." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-17916103-eptifibatide-v1 SHA-256: 3640fcbfb7d98fbb86e867875e77e902ae420ac1746a3a2f33f00aae07d208d8.

---

<a id="pubmed-pmid-18078431-eptifibatide-v1"></a>

## A review of clinical trials with eptifibatide in cardiology.

> PubMed lists PMID 18078431 in Cardiovascular drug reviews as Journal Article, Review, with publication-date metadata of 2007 Winter (source-text precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18078431-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18078431-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-18078431-eptifibatide-v1
- Content SHA-256: `34ecac7baad81936041aedb54095be59d8baacc725b6a1dbc814af8e9a916e90`

### Claims and source pins

#### Headline

A review of clinical trials with eptifibatide in cardiology. ([`pubmed-observation-pmid-18078431-2018-12-01-3013d684b8cd`](#source-pubmed-observation-pmid-18078431-2018-12-01-3013d684b8cd))

#### Summary

PubMed lists PMID 18078431 in Cardiovascular drug reviews as Journal Article, Review, with publication-date metadata of 2007 Winter (source-text precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18078431-2018-12-01-3013d684b8cd`](#source-pubmed-observation-pmid-18078431-2018-12-01-3013d684b8cd))

#### Paragraph 1

PubMed lists PMID 18078431 in Cardiovascular drug reviews as Journal Article, Review, with publication-date metadata of 2007 Winter (source-text precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18078431-2018-12-01-3013d684b8cd`](#source-pubmed-observation-pmid-18078431-2018-12-01-3013d684b8cd))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18078431-2018-12-01-3013d684b8cd`](#source-pubmed-observation-pmid-18078431-2018-12-01-3013d684b8cd))

### Sources

<a id="source-pubmed-observation-pmid-18078431-2018-12-01-3013d684b8cd"></a>
- **A review of clinical trials with eptifibatide in cardiology. · retained source version 1:2018-12-01:current:3013d684b8cd87be9075da5ebe40d1383d871c4059ec36bc0dd192998bfcb399** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18078431/) (`pubmed-observation-pmid-18078431-2018-12-01-3013d684b8cd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A review of clinical trials with eptifibatide in cardiology." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-18078431-eptifibatide-v1 SHA-256: 34ecac7baad81936041aedb54095be59d8baacc725b6a1dbc814af8e9a916e90.

---

<a id="pubmed-pmid-18772447-eptifibatide-v1"></a>

## The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial.

> PubMed lists PMID 18772447 in Stroke as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2008-09-04 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18772447-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18772447-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-18772447-eptifibatide-v1
- Content SHA-256: `229d2cb9c58b5949ab585bc5ee0796dfa00a1b335606cecd3c7e67d75a767e93`

### Claims and source pins

#### Headline

The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. ([`pubmed-observation-pmid-18772447-2026-05-18-4e0c11947bf6`](#source-pubmed-observation-pmid-18772447-2026-05-18-4e0c11947bf6))

#### Summary

PubMed lists PMID 18772447 in Stroke as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2008-09-04 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18772447-2026-05-18-4e0c11947bf6`](#source-pubmed-observation-pmid-18772447-2026-05-18-4e0c11947bf6))

#### Paragraph 1

PubMed lists PMID 18772447 in Stroke as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2008-09-04 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18772447-2026-05-18-4e0c11947bf6`](#source-pubmed-observation-pmid-18772447-2026-05-18-4e0c11947bf6))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18772447-2026-05-18-4e0c11947bf6`](#source-pubmed-observation-pmid-18772447-2026-05-18-4e0c11947bf6))

### Sources

<a id="source-pubmed-observation-pmid-18772447-2026-05-18-4e0c11947bf6"></a>
- **The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. · retained source version 1:2026-05-18:current:4e0c11947bf6576c6855c9dbec31a8adbd2c788782e7c84857151578855ed1db** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18772447/) (`pubmed-observation-pmid-18772447-2026-05-18-4e0c11947bf6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-18772447-eptifibatide-v1 SHA-256: 229d2cb9c58b5949ab585bc5ee0796dfa00a1b335606cecd3c7e67d75a767e93.

---

<a id="pubmed-pmid-21127429-eptifibatide-v1"></a>

## Comparison of ecchymosis rates with measurement of automated and manual blood pressures in patients receiving eptifibatide therapy.

> PubMed lists PMID 21127429 in The Journal of cardiovascular nursing as Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2011 Jan-Feb (source-text precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-21127429-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-21127429-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-21127429-eptifibatide-v1
- Content SHA-256: `0fae765f2efa9cac66a6f45fda71a90186ceb61815136bc4062fc6384c45e6e9`

### Claims and source pins

#### Headline

Comparison of ecchymosis rates with measurement of automated and manual blood pressures in patients receiving eptifibatide therapy. ([`pubmed-observation-pmid-21127429-2018-12-02-d541a31b93e0`](#source-pubmed-observation-pmid-21127429-2018-12-02-d541a31b93e0))

#### Summary

PubMed lists PMID 21127429 in The Journal of cardiovascular nursing as Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2011 Jan-Feb (source-text precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-21127429-2018-12-02-d541a31b93e0`](#source-pubmed-observation-pmid-21127429-2018-12-02-d541a31b93e0))

#### Paragraph 1

PubMed lists PMID 21127429 in The Journal of cardiovascular nursing as Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2011 Jan-Feb (source-text precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-21127429-2018-12-02-d541a31b93e0`](#source-pubmed-observation-pmid-21127429-2018-12-02-d541a31b93e0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-21127429-2018-12-02-d541a31b93e0`](#source-pubmed-observation-pmid-21127429-2018-12-02-d541a31b93e0))

### Sources

<a id="source-pubmed-observation-pmid-21127429-2018-12-02-d541a31b93e0"></a>
- **Comparison of ecchymosis rates with measurement of automated and manual blood pressures in patients receiving eptifibatide therapy. · retained source version 1:2018-12-02:current:d541a31b93e0f35edeb01f7ca45f1730f2b50c9784ad53574d1029d88c6e79aa** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/21127429/) (`pubmed-observation-pmid-21127429-2018-12-02-d541a31b93e0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Comparison of ecchymosis rates with measurement of automated and manual blood pressures in patients receiving eptifibatide therapy." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-21127429-eptifibatide-v1 SHA-256: 0fae765f2efa9cac66a6f45fda71a90186ceb61815136bc4062fc6384c45e6e9.

---

<a id="pubmed-pmid-22137072-eptifibatide-v1"></a>

## The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial.

> PubMed lists PMID 22137072 in American heart journal as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2011-11-08 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22137072-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-10-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22137072-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-22137072-eptifibatide-v1
- Content SHA-256: `c80bc1579dbad7210684da660f0870a4dd5e64a2544527445a8e04ff1b4a9187`

### Claims and source pins

#### Headline

The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial. ([`pubmed-observation-pmid-22137072-2021-10-21-235ee5e0f3bf`](#source-pubmed-observation-pmid-22137072-2021-10-21-235ee5e0f3bf))

#### Summary

PubMed lists PMID 22137072 in American heart journal as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2011-11-08 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22137072-2021-10-21-235ee5e0f3bf`](#source-pubmed-observation-pmid-22137072-2021-10-21-235ee5e0f3bf))

#### Paragraph 1

PubMed lists PMID 22137072 in American heart journal as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2011-11-08 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22137072-2021-10-21-235ee5e0f3bf`](#source-pubmed-observation-pmid-22137072-2021-10-21-235ee5e0f3bf))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22137072-2021-10-21-235ee5e0f3bf`](#source-pubmed-observation-pmid-22137072-2021-10-21-235ee5e0f3bf))

### Sources

<a id="source-pubmed-observation-pmid-22137072-2021-10-21-235ee5e0f3bf"></a>
- **The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial. · retained source version 1:2021-10-21:current:235ee5e0f3bf4cb1ece50ed38c33d6f4f52ddbb444627a43209f18c4b266f306** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22137072/) (`pubmed-observation-pmid-22137072-2021-10-21-235ee5e0f3bf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-22137072-eptifibatide-v1 SHA-256: c80bc1579dbad7210684da660f0870a4dd5e64a2544527445a8e04ff1b4a9187.

---

<a id="pubmed-pmid-22607870-eptifibatide-v1"></a>

## Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: the INtegrilin plus STenting to Avoid myocardial Necrosis Trial.

> PubMed lists PMID 22607870 in American heart journal as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-05 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22607870-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22607870-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-22607870-eptifibatide-v1
- Content SHA-256: `81b8269f40ab020c22e0875b610ce467c185e34d197f9b8ea702d4dc90624a3b`

### Claims and source pins

#### Headline

Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: the INtegrilin plus STenting to Avoid myocardial Necrosis Trial. ([`pubmed-observation-pmid-22607870-2018-12-01-b543a827aae7`](#source-pubmed-observation-pmid-22607870-2018-12-01-b543a827aae7))

#### Summary

PubMed lists PMID 22607870 in American heart journal as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-05 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22607870-2018-12-01-b543a827aae7`](#source-pubmed-observation-pmid-22607870-2018-12-01-b543a827aae7))

#### Paragraph 1

PubMed lists PMID 22607870 in American heart journal as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-05 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22607870-2018-12-01-b543a827aae7`](#source-pubmed-observation-pmid-22607870-2018-12-01-b543a827aae7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22607870-2018-12-01-b543a827aae7`](#source-pubmed-observation-pmid-22607870-2018-12-01-b543a827aae7))

### Sources

<a id="source-pubmed-observation-pmid-22607870-2018-12-01-b543a827aae7"></a>
- **Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: the INtegrilin plus STenting to Avoid myocardial Necrosis Trial. · retained source version 1:2018-12-01:current:b543a827aae7ddd2e17c85fd98c42876e1bbaaabd0233295d665f2579c5e647e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22607870/) (`pubmed-observation-pmid-22607870-2018-12-01-b543a827aae7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: the INtegrilin plus STenting to Avoid myocardial Necrosis Trial." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-22607870-eptifibatide-v1 SHA-256: 81b8269f40ab020c22e0875b610ce467c185e34d197f9b8ea702d4dc90624a3b.

---

<a id="pubmed-pmid-23973010-eptifibatide-v1"></a>

## A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease.

> PubMed lists PMID 23973010 in Thrombosis research as Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2013-08-08 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23973010-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-06-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23973010-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-23973010-eptifibatide-v1
- Content SHA-256: `b9a82e5d867c3aca8f99ce2b0b5380d7d5d4e34c1ab7fd9fa1c215f382bede21`

### Claims and source pins

#### Headline

A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease. ([`pubmed-observation-pmid-23973010-2024-06-10-5a88dc3047e4`](#source-pubmed-observation-pmid-23973010-2024-06-10-5a88dc3047e4))

#### Summary

PubMed lists PMID 23973010 in Thrombosis research as Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2013-08-08 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23973010-2024-06-10-5a88dc3047e4`](#source-pubmed-observation-pmid-23973010-2024-06-10-5a88dc3047e4))

#### Paragraph 1

PubMed lists PMID 23973010 in Thrombosis research as Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2013-08-08 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23973010-2024-06-10-5a88dc3047e4`](#source-pubmed-observation-pmid-23973010-2024-06-10-5a88dc3047e4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23973010-2024-06-10-5a88dc3047e4`](#source-pubmed-observation-pmid-23973010-2024-06-10-5a88dc3047e4))

### Sources

<a id="source-pubmed-observation-pmid-23973010-2024-06-10-5a88dc3047e4"></a>
- **A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease. · retained source version 1:2024-06-10:current:5a88dc3047e488057c178036bbefe5873ec4f2454c994e040ac64989489ee770** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23973010/) (`pubmed-observation-pmid-23973010-2024-06-10-5a88dc3047e4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-23973010-eptifibatide-v1 SHA-256: b9a82e5d867c3aca8f99ce2b0b5380d7d5d4e34c1ab7fd9fa1c215f382bede21.

---

<a id="pubmed-pmid-24534128-eptifibatide-v1"></a>

## A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke.

> PubMed lists PMID 24534128 in Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2014-02-15 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-24534128-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-24534128-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-24534128-eptifibatide-v1
- Content SHA-256: `f543df6a3d82cbc6c7dceca70049843c72a45cc9cc8dc2de818268c8ed212725`

### Claims and source pins

#### Headline

A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke. ([`pubmed-observation-pmid-24534128-2026-01-28-02b314668d69`](#source-pubmed-observation-pmid-24534128-2026-01-28-02b314668d69))

#### Summary

PubMed lists PMID 24534128 in Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2014-02-15 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24534128-2026-01-28-02b314668d69`](#source-pubmed-observation-pmid-24534128-2026-01-28-02b314668d69))

#### Paragraph 1

PubMed lists PMID 24534128 in Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2014-02-15 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24534128-2026-01-28-02b314668d69`](#source-pubmed-observation-pmid-24534128-2026-01-28-02b314668d69))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-24534128-2026-01-28-02b314668d69`](#source-pubmed-observation-pmid-24534128-2026-01-28-02b314668d69))

### Sources

<a id="source-pubmed-observation-pmid-24534128-2026-01-28-02b314668d69"></a>
- **A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke. · retained source version 1:2026-01-28:current:02b314668d693871212d2a56630eab597668eed9637231a8e75f2d6550bc2a57** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/24534128/) (`pubmed-observation-pmid-24534128-2026-01-28-02b314668d69`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-24534128-eptifibatide-v1 SHA-256: f543df6a3d82cbc6c7dceca70049843c72a45cc9cc8dc2de818268c8ed212725.

---

<a id="pubmed-pmid-25090985-eptifibatide-v1"></a>

## αIIbβ3-integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells.

> PubMed lists PMID 25090985 in Current drug targets as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015 (year precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-25090985-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-09-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25090985-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-25090985-eptifibatide-v1
- Content SHA-256: `1209c821b189e0c9d56cf988deb74da7ecc9cdbf2f66cefb32e26a7ccf17f680`

### Claims and source pins

#### Headline

αIIbβ3-integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells. ([`pubmed-observation-pmid-25090985-2019-09-11-b88a58c169c9`](#source-pubmed-observation-pmid-25090985-2019-09-11-b88a58c169c9))

#### Summary

PubMed lists PMID 25090985 in Current drug targets as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015 (year precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25090985-2019-09-11-b88a58c169c9`](#source-pubmed-observation-pmid-25090985-2019-09-11-b88a58c169c9))

#### Paragraph 1

PubMed lists PMID 25090985 in Current drug targets as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015 (year precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25090985-2019-09-11-b88a58c169c9`](#source-pubmed-observation-pmid-25090985-2019-09-11-b88a58c169c9))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25090985-2019-09-11-b88a58c169c9`](#source-pubmed-observation-pmid-25090985-2019-09-11-b88a58c169c9))

### Sources

<a id="source-pubmed-observation-pmid-25090985-2019-09-11-b88a58c169c9"></a>
- **αIIbβ3-integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells. · retained source version 1:2019-09-11:current:b88a58c169c9673ca0afa40c88c3b34248d1c3c1fc9e1e5a4f43288e19111745** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25090985/) (`pubmed-observation-pmid-25090985-2019-09-11-b88a58c169c9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "αIIbβ3-integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-25090985-eptifibatide-v1 SHA-256: 1209c821b189e0c9d56cf988deb74da7ecc9cdbf2f66cefb32e26a7ccf17f680.

---

<a id="pubmed-pmid-25523054-eptifibatide-v1"></a>

## Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis.

> PubMed lists PMID 25523054 in Stroke as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2014-12-18 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-25523054-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-01-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25523054-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-25523054-eptifibatide-v1
- Content SHA-256: `263bb0190a5071909c62ac343dafdb3fcaf6921ed765e9b1c1587f74cbc02115`

### Claims and source pins

#### Headline

Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis. ([`pubmed-observation-pmid-25523054-2021-01-05-114f4668942b`](#source-pubmed-observation-pmid-25523054-2021-01-05-114f4668942b))

#### Summary

PubMed lists PMID 25523054 in Stroke as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2014-12-18 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25523054-2021-01-05-114f4668942b`](#source-pubmed-observation-pmid-25523054-2021-01-05-114f4668942b))

#### Paragraph 1

PubMed lists PMID 25523054 in Stroke as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2014-12-18 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25523054-2021-01-05-114f4668942b`](#source-pubmed-observation-pmid-25523054-2021-01-05-114f4668942b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25523054-2021-01-05-114f4668942b`](#source-pubmed-observation-pmid-25523054-2021-01-05-114f4668942b))

### Sources

<a id="source-pubmed-observation-pmid-25523054-2021-01-05-114f4668942b"></a>
- **Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis. · retained source version 1:2021-01-05:current:114f4668942b8ac923e10c9bc91227d648bb473cbde5909e6a585313a621ea27** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25523054/) (`pubmed-observation-pmid-25523054-2021-01-05-114f4668942b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-25523054-eptifibatide-v1 SHA-256: 263bb0190a5071909c62ac343dafdb3fcaf6921ed765e9b1c1587f74cbc02115.

---

<a id="pubmed-pmid-25657317-eptifibatide-v1"></a>

## Eptifibatide in coronary intervention: past time for the next chapter.

> PubMed lists PMID 25657317 in Circulation. Cardiovascular interventions as Editorial, Comment, with publication-date metadata of 2015-02 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-25657317-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25657317-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-25657317-eptifibatide-v1
- Content SHA-256: `78dacbe882e076333ae27e870e1d99954089164fc23805b64e4e4438c53682c5`

### Claims and source pins

#### Headline

Eptifibatide in coronary intervention: past time for the next chapter. ([`pubmed-observation-pmid-25657317-2018-12-02-85e71b733551`](#source-pubmed-observation-pmid-25657317-2018-12-02-85e71b733551))

#### Summary

PubMed lists PMID 25657317 in Circulation. Cardiovascular interventions as Editorial, Comment, with publication-date metadata of 2015-02 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25657317-2018-12-02-85e71b733551`](#source-pubmed-observation-pmid-25657317-2018-12-02-85e71b733551))

#### Paragraph 1

PubMed lists PMID 25657317 in Circulation. Cardiovascular interventions as Editorial, Comment, with publication-date metadata of 2015-02 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25657317-2018-12-02-85e71b733551`](#source-pubmed-observation-pmid-25657317-2018-12-02-85e71b733551))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25657317-2018-12-02-85e71b733551`](#source-pubmed-observation-pmid-25657317-2018-12-02-85e71b733551))

### Sources

<a id="source-pubmed-observation-pmid-25657317-2018-12-02-85e71b733551"></a>
- **Eptifibatide in coronary intervention: past time for the next chapter. · retained source version 1:2018-12-02:current:85e71b73355144f0713c955288755f34ad9f255a74d00a0ef8933e721756f620** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25657317/) (`pubmed-observation-pmid-25657317-2018-12-02-85e71b733551`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Eptifibatide in coronary intervention: past time for the next chapter." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-25657317-eptifibatide-v1 SHA-256: 78dacbe882e076333ae27e870e1d99954089164fc23805b64e4e4438c53682c5.

---

<a id="pubmed-pmid-25857672-eptifibatide-v1"></a>

## Using Zero-Balance Ultrafiltration With Dialysate as a Replacement Solution for Toxin and Eptifibatide Removal on a Dialysis-Dependent Patient During Cardiopulmonary Bypass.

> PubMed lists PMID 25857672 in Journal of cardiothoracic and vascular anesthesia as Case Reports, Journal Article, with publication-date metadata of 2014-12-08 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-25857672-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25857672-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-25857672-eptifibatide-v1
- Content SHA-256: `d53fab4393159cef832796b138274df8b4440dfebf054e583e41905d8ff532c9`

### Claims and source pins

#### Headline

Using Zero-Balance Ultrafiltration With Dialysate as a Replacement Solution for Toxin and Eptifibatide Removal on a Dialysis-Dependent Patient During Cardiopulmonary Bypass. ([`pubmed-observation-pmid-25857672-2018-12-02-12f6596be01b`](#source-pubmed-observation-pmid-25857672-2018-12-02-12f6596be01b))

#### Summary

PubMed lists PMID 25857672 in Journal of cardiothoracic and vascular anesthesia as Case Reports, Journal Article, with publication-date metadata of 2014-12-08 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25857672-2018-12-02-12f6596be01b`](#source-pubmed-observation-pmid-25857672-2018-12-02-12f6596be01b))

#### Paragraph 1

PubMed lists PMID 25857672 in Journal of cardiothoracic and vascular anesthesia as Case Reports, Journal Article, with publication-date metadata of 2014-12-08 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25857672-2018-12-02-12f6596be01b`](#source-pubmed-observation-pmid-25857672-2018-12-02-12f6596be01b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25857672-2018-12-02-12f6596be01b`](#source-pubmed-observation-pmid-25857672-2018-12-02-12f6596be01b))

### Sources

<a id="source-pubmed-observation-pmid-25857672-2018-12-02-12f6596be01b"></a>
- **Using Zero-Balance Ultrafiltration With Dialysate as a Replacement Solution for Toxin and Eptifibatide Removal on a Dialysis-Dependent Patient During Cardiopulmonary Bypass. · retained source version 1:2018-12-02:current:12f6596be01be8da09913e110cfac6686934f1554ef25bff03bee2a74a281833** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25857672/) (`pubmed-observation-pmid-25857672-2018-12-02-12f6596be01b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Using Zero-Balance Ultrafiltration With Dialysate as a Replacement Solution for Toxin and Eptifibatide Removal on a Dialysis-Dependent Patient During Cardiopulmonary Bypass." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-25857672-eptifibatide-v1 SHA-256: d53fab4393159cef832796b138274df8b4440dfebf054e583e41905d8ff532c9.

---

<a id="pubmed-pmid-25892271-eptifibatide-v1"></a>

## Eptifibatide in post-infarction angina patients who refused intervention: Ajmer postmyocardial infarction angina eptifibatide research (AJMER) study: a pilot study.

> PubMed lists PMID 25892271 in Cardiovascular therapeutics as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2015-08 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-25892271-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25892271-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-25892271-eptifibatide-v1
- Content SHA-256: `49bc8d41e85704602b44d2d74b753110e6e086246931928357a004c81757c8b5`

### Claims and source pins

#### Headline

Eptifibatide in post-infarction angina patients who refused intervention: Ajmer postmyocardial infarction angina eptifibatide research (AJMER) study: a pilot study. ([`pubmed-observation-pmid-25892271-2026-01-28-dc9ab2b1b18e`](#source-pubmed-observation-pmid-25892271-2026-01-28-dc9ab2b1b18e))

#### Summary

PubMed lists PMID 25892271 in Cardiovascular therapeutics as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2015-08 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25892271-2026-01-28-dc9ab2b1b18e`](#source-pubmed-observation-pmid-25892271-2026-01-28-dc9ab2b1b18e))

#### Paragraph 1

PubMed lists PMID 25892271 in Cardiovascular therapeutics as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2015-08 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25892271-2026-01-28-dc9ab2b1b18e`](#source-pubmed-observation-pmid-25892271-2026-01-28-dc9ab2b1b18e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25892271-2026-01-28-dc9ab2b1b18e`](#source-pubmed-observation-pmid-25892271-2026-01-28-dc9ab2b1b18e))

### Sources

<a id="source-pubmed-observation-pmid-25892271-2026-01-28-dc9ab2b1b18e"></a>
- **Eptifibatide in post-infarction angina patients who refused intervention: Ajmer postmyocardial infarction angina eptifibatide research (AJMER) study: a pilot study. · retained source version 1:2026-01-28:current:dc9ab2b1b18e2a22b7e7a41539f4d009fcadf7f018bcf3891124031d8d06d55c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25892271/) (`pubmed-observation-pmid-25892271-2026-01-28-dc9ab2b1b18e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Eptifibatide in post-infarction angina patients who refused intervention: Ajmer postmyocardial infarction angina eptifibatide research (AJMER) study: a pilot study." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-25892271-eptifibatide-v1 SHA-256: 49bc8d41e85704602b44d2d74b753110e6e086246931928357a004c81757c8b5.

---

<a id="pubmed-pmid-28423263-eptifibatide-v1"></a>

## \[EXPERIENCE WITH THE USE OF EPTIFIBATIDE IN ACUTE CORONARY SYNDROME DURING CORONARY INTERVENTION IN PATIENTS OLDER AGE GROUP\].

> PubMed lists PMID 28423263 in Advances in gerontology = Uspekhi gerontologii as Journal Article, with publication-date metadata of 2016 (year precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28423263-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28423263-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-28423263-eptifibatide-v1
- Content SHA-256: `0880d7f5e38564ab42da12976a679d1dee5382a7d04fa09aea95c7580294d996`

### Claims and source pins

#### Headline

\[EXPERIENCE WITH THE USE OF EPTIFIBATIDE IN ACUTE CORONARY SYNDROME DURING CORONARY INTERVENTION IN PATIENTS OLDER AGE GROUP\]. ([`pubmed-observation-pmid-28423263-2018-12-02-5b738af0a671`](#source-pubmed-observation-pmid-28423263-2018-12-02-5b738af0a671))

#### Summary

PubMed lists PMID 28423263 in Advances in gerontology = Uspekhi gerontologii as Journal Article, with publication-date metadata of 2016 (year precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28423263-2018-12-02-5b738af0a671`](#source-pubmed-observation-pmid-28423263-2018-12-02-5b738af0a671))

#### Paragraph 1

PubMed lists PMID 28423263 in Advances in gerontology = Uspekhi gerontologii as Journal Article, with publication-date metadata of 2016 (year precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28423263-2018-12-02-5b738af0a671`](#source-pubmed-observation-pmid-28423263-2018-12-02-5b738af0a671))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28423263-2018-12-02-5b738af0a671`](#source-pubmed-observation-pmid-28423263-2018-12-02-5b738af0a671))

### Sources

<a id="source-pubmed-observation-pmid-28423263-2018-12-02-5b738af0a671"></a>
- **\[EXPERIENCE WITH THE USE OF EPTIFIBATIDE IN ACUTE CORONARY SYNDROME DURING CORONARY INTERVENTION IN PATIENTS OLDER AGE GROUP\]. · retained source version 1:2018-12-02:current:5b738af0a6717e3087773a3fa7e393b36c53399cef5030f1b64bd561b70b2681** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28423263/) (`pubmed-observation-pmid-28423263-2018-12-02-5b738af0a671`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[EXPERIENCE WITH THE USE OF EPTIFIBATIDE IN ACUTE CORONARY SYNDROME DURING CORONARY INTERVENTION IN PATIENTS OLDER AGE GROUP\]." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-28423263-eptifibatide-v1 SHA-256: 0880d7f5e38564ab42da12976a679d1dee5382a7d04fa09aea95c7580294d996.

---

<a id="pubmed-pmid-28621461-eptifibatide-v1"></a>

## The Use of Eptifibatide Alone or in Combination With Heparin or Argatroban for Suspected Thrombosis in Patients With Left Ventricular Assist Devices.

> PubMed lists PMID 28621461 in Artificial organs as Journal Article, with publication-date metadata of 2017-06-16 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28621461-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-12-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28621461-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-28621461-eptifibatide-v1
- Content SHA-256: `5921a671710bf792e799cc3881a0abef12c9ed34383b9002c03ed175ed091041`

### Claims and source pins

#### Headline

The Use of Eptifibatide Alone or in Combination With Heparin or Argatroban for Suspected Thrombosis in Patients With Left Ventricular Assist Devices. ([`pubmed-observation-pmid-28621461-2020-12-09-c948d0150ded`](#source-pubmed-observation-pmid-28621461-2020-12-09-c948d0150ded))

#### Summary

PubMed lists PMID 28621461 in Artificial organs as Journal Article, with publication-date metadata of 2017-06-16 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28621461-2020-12-09-c948d0150ded`](#source-pubmed-observation-pmid-28621461-2020-12-09-c948d0150ded))

#### Paragraph 1

PubMed lists PMID 28621461 in Artificial organs as Journal Article, with publication-date metadata of 2017-06-16 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28621461-2020-12-09-c948d0150ded`](#source-pubmed-observation-pmid-28621461-2020-12-09-c948d0150ded))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28621461-2020-12-09-c948d0150ded`](#source-pubmed-observation-pmid-28621461-2020-12-09-c948d0150ded))

### Sources

<a id="source-pubmed-observation-pmid-28621461-2020-12-09-c948d0150ded"></a>
- **The Use of Eptifibatide Alone or in Combination With Heparin or Argatroban for Suspected Thrombosis in Patients With Left Ventricular Assist Devices. · retained source version 1:2020-12-09:current:c948d0150dedffedae552b83098c79e7fe4a249993fb4dab5d579d20635120a6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28621461/) (`pubmed-observation-pmid-28621461-2020-12-09-c948d0150ded`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The Use of Eptifibatide Alone or in Combination With Heparin or Argatroban for Suspected Thrombosis in Patients With Left Ventricular Assist Devices." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-28621461-eptifibatide-v1 SHA-256: 5921a671710bf792e799cc3881a0abef12c9ed34383b9002c03ed175ed091041.

---

<a id="pubmed-pmid-28959324-eptifibatide-v1"></a>

## Optimization of RGD-modified Nano-liposomes Encapsulating Eptifibatide.

> PubMed lists PMID 28959324 in Iranian journal of biotechnology as Journal Article, with publication-date metadata of 2016-06 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28959324-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-04-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28959324-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-28959324-eptifibatide-v1
- Content SHA-256: `50ac20ae20cd57a970d164baa75595a19a3c1a13df818e89294ff804edebdb9d`

### Claims and source pins

#### Headline

Optimization of RGD-modified Nano-liposomes Encapsulating Eptifibatide. ([`pubmed-observation-pmid-28959324-2022-04-10-68f47206e28d`](#source-pubmed-observation-pmid-28959324-2022-04-10-68f47206e28d))

#### Summary

PubMed lists PMID 28959324 in Iranian journal of biotechnology as Journal Article, with publication-date metadata of 2016-06 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28959324-2022-04-10-68f47206e28d`](#source-pubmed-observation-pmid-28959324-2022-04-10-68f47206e28d))

#### Paragraph 1

PubMed lists PMID 28959324 in Iranian journal of biotechnology as Journal Article, with publication-date metadata of 2016-06 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28959324-2022-04-10-68f47206e28d`](#source-pubmed-observation-pmid-28959324-2022-04-10-68f47206e28d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28959324-2022-04-10-68f47206e28d`](#source-pubmed-observation-pmid-28959324-2022-04-10-68f47206e28d))

### Sources

<a id="source-pubmed-observation-pmid-28959324-2022-04-10-68f47206e28d"></a>
- **Optimization of RGD-modified Nano-liposomes Encapsulating Eptifibatide. · retained source version 1:2022-04-10:current:68f47206e28d91dfe0dbdb1ed6d817292d4c3d835394681363824478eb13b753** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28959324/) (`pubmed-observation-pmid-28959324-2022-04-10-68f47206e28d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Optimization of RGD-modified Nano-liposomes Encapsulating Eptifibatide." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-28959324-eptifibatide-v1 SHA-256: 50ac20ae20cd57a970d164baa75595a19a3c1a13df818e89294ff804edebdb9d.

---

<a id="pubmed-pmid-29874954-eptifibatide-v1"></a>

## Prolonged use of eptifibatide as a bridge to maintain drug-eluting stent patency in a patient receiving extracorporeal membrane oxygenation.

> PubMed lists PMID 29874954 in Perfusion as Case Reports, Journal Article, with publication-date metadata of 2018-06-06 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29874954-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-19
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29874954-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-29874954-eptifibatide-v1
- Content SHA-256: `692a87215832d96d234422c2bde0545f445435c285f6d6359541709cac395277`

### Claims and source pins

#### Headline

Prolonged use of eptifibatide as a bridge to maintain drug-eluting stent patency in a patient receiving extracorporeal membrane oxygenation. ([`pubmed-observation-pmid-29874954-2018-12-19-5e1c31d1e479`](#source-pubmed-observation-pmid-29874954-2018-12-19-5e1c31d1e479))

#### Summary

PubMed lists PMID 29874954 in Perfusion as Case Reports, Journal Article, with publication-date metadata of 2018-06-06 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29874954-2018-12-19-5e1c31d1e479`](#source-pubmed-observation-pmid-29874954-2018-12-19-5e1c31d1e479))

#### Paragraph 1

PubMed lists PMID 29874954 in Perfusion as Case Reports, Journal Article, with publication-date metadata of 2018-06-06 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29874954-2018-12-19-5e1c31d1e479`](#source-pubmed-observation-pmid-29874954-2018-12-19-5e1c31d1e479))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29874954-2018-12-19-5e1c31d1e479`](#source-pubmed-observation-pmid-29874954-2018-12-19-5e1c31d1e479))

### Sources

<a id="source-pubmed-observation-pmid-29874954-2018-12-19-5e1c31d1e479"></a>
- **Prolonged use of eptifibatide as a bridge to maintain drug-eluting stent patency in a patient receiving extracorporeal membrane oxygenation. · retained source version 1:2018-12-19:current:5e1c31d1e479c9ad160605f57c3ffdad39871e70ac7488201ccc06067865a253** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29874954/) (`pubmed-observation-pmid-29874954-2018-12-19-5e1c31d1e479`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Prolonged use of eptifibatide as a bridge to maintain drug-eluting stent patency in a patient receiving extracorporeal membrane oxygenation." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-29874954-eptifibatide-v1 SHA-256: 692a87215832d96d234422c2bde0545f445435c285f6d6359541709cac395277.

---

<a id="pubmed-pmid-31004428-eptifibatide-v1"></a>

## Validated High Performance Liquid Chromatographic Method for Stability Study of Eptifibatide.

> PubMed lists PMID 31004428 in Journal of chromatographic science as Journal Article, with publication-date metadata of 2019-07-01 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31004428-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-09-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31004428-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-31004428-eptifibatide-v1
- Content SHA-256: `e25d5020f3fd0200077b2669d8977e00f466f46880bc69d67b7a9879354a147c`

### Claims and source pins

#### Headline

Validated High Performance Liquid Chromatographic Method for Stability Study of Eptifibatide. ([`pubmed-observation-pmid-31004428-2019-09-02-8fcdaecde2b4`](#source-pubmed-observation-pmid-31004428-2019-09-02-8fcdaecde2b4))

#### Summary

PubMed lists PMID 31004428 in Journal of chromatographic science as Journal Article, with publication-date metadata of 2019-07-01 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31004428-2019-09-02-8fcdaecde2b4`](#source-pubmed-observation-pmid-31004428-2019-09-02-8fcdaecde2b4))

#### Paragraph 1

PubMed lists PMID 31004428 in Journal of chromatographic science as Journal Article, with publication-date metadata of 2019-07-01 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31004428-2019-09-02-8fcdaecde2b4`](#source-pubmed-observation-pmid-31004428-2019-09-02-8fcdaecde2b4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31004428-2019-09-02-8fcdaecde2b4`](#source-pubmed-observation-pmid-31004428-2019-09-02-8fcdaecde2b4))

### Sources

<a id="source-pubmed-observation-pmid-31004428-2019-09-02-8fcdaecde2b4"></a>
- **Validated High Performance Liquid Chromatographic Method for Stability Study of Eptifibatide. · retained source version 1:2019-09-02:current:8fcdaecde2b486d4ef594139a23cc0546c324efaf7bba43eb1fb616021f3168e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31004428/) (`pubmed-observation-pmid-31004428-2019-09-02-8fcdaecde2b4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Validated High Performance Liquid Chromatographic Method for Stability Study of Eptifibatide." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-31004428-eptifibatide-v1 SHA-256: e25d5020f3fd0200077b2669d8977e00f466f46880bc69d67b7a9879354a147c.

---

<a id="pubmed-pmid-31724642-eptifibatide-v1"></a>

## Tibial bypass salvage with eptifibatide in a patient with thrombocythemia.

> PubMed lists PMID 31724642 in Journal of vascular surgery cases as Case Reports, Journal Article, with publication-date metadata of 2015-11-01 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31724642-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-09-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31724642-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-31724642-eptifibatide-v1
- Content SHA-256: `c0b333e20d791524afb32a8f3348777b4b1b968316815b46feeae05f4adc9313`

### Claims and source pins

#### Headline

Tibial bypass salvage with eptifibatide in a patient with thrombocythemia. ([`pubmed-observation-pmid-31724642-2020-09-29-1216cafdbae1`](#source-pubmed-observation-pmid-31724642-2020-09-29-1216cafdbae1))

#### Summary

PubMed lists PMID 31724642 in Journal of vascular surgery cases as Case Reports, Journal Article, with publication-date metadata of 2015-11-01 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31724642-2020-09-29-1216cafdbae1`](#source-pubmed-observation-pmid-31724642-2020-09-29-1216cafdbae1))

#### Paragraph 1

PubMed lists PMID 31724642 in Journal of vascular surgery cases as Case Reports, Journal Article, with publication-date metadata of 2015-11-01 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31724642-2020-09-29-1216cafdbae1`](#source-pubmed-observation-pmid-31724642-2020-09-29-1216cafdbae1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31724642-2020-09-29-1216cafdbae1`](#source-pubmed-observation-pmid-31724642-2020-09-29-1216cafdbae1))

### Sources

<a id="source-pubmed-observation-pmid-31724642-2020-09-29-1216cafdbae1"></a>
- **Tibial bypass salvage with eptifibatide in a patient with thrombocythemia. · retained source version 1:2020-09-29:current:1216cafdbae1c57846c4f0d05e3dba205bc167c615a159ef2e7a65fd77469167** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31724642/) (`pubmed-observation-pmid-31724642-2020-09-29-1216cafdbae1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tibial bypass salvage with eptifibatide in a patient with thrombocythemia." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-31724642-eptifibatide-v1 SHA-256: c0b333e20d791524afb32a8f3348777b4b1b968316815b46feeae05f4adc9313.

---

<a id="pubmed-pmid-32807436-eptifibatide-v1"></a>

## Eptifibatide use following emergent carotid stenting in acute anterior circulation ischemic stroke with tandem occlusion.

> PubMed lists PMID 32807436 in Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association as Journal Article, with publication-date metadata of 2020-06-17 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32807436-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-11-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32807436-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-32807436-eptifibatide-v1
- Content SHA-256: `687a3da2947b18431a56e7f4de983fd916d1008ce6f31e0d31a74f5f40dc48af`

### Claims and source pins

#### Headline

Eptifibatide use following emergent carotid stenting in acute anterior circulation ischemic stroke with tandem occlusion. ([`pubmed-observation-pmid-32807436-2020-11-02-ee8ccd877654`](#source-pubmed-observation-pmid-32807436-2020-11-02-ee8ccd877654))

#### Summary

PubMed lists PMID 32807436 in Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association as Journal Article, with publication-date metadata of 2020-06-17 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32807436-2020-11-02-ee8ccd877654`](#source-pubmed-observation-pmid-32807436-2020-11-02-ee8ccd877654))

#### Paragraph 1

PubMed lists PMID 32807436 in Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association as Journal Article, with publication-date metadata of 2020-06-17 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32807436-2020-11-02-ee8ccd877654`](#source-pubmed-observation-pmid-32807436-2020-11-02-ee8ccd877654))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32807436-2020-11-02-ee8ccd877654`](#source-pubmed-observation-pmid-32807436-2020-11-02-ee8ccd877654))

### Sources

<a id="source-pubmed-observation-pmid-32807436-2020-11-02-ee8ccd877654"></a>
- **Eptifibatide use following emergent carotid stenting in acute anterior circulation ischemic stroke with tandem occlusion. · retained source version 1:2020-11-02:current:ee8ccd87765407b9c5bf9cfec62a6783f65d88c6cfe9d6668cdec8e026481d93** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32807436/) (`pubmed-observation-pmid-32807436-2020-11-02-ee8ccd877654`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Eptifibatide use following emergent carotid stenting in acute anterior circulation ischemic stroke with tandem occlusion." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-32807436-eptifibatide-v1 SHA-256: 687a3da2947b18431a56e7f4de983fd916d1008ce6f31e0d31a74f5f40dc48af.

---

<a id="pubmed-pmid-34462026-eptifibatide-v1"></a>

## Acute intraprocedural thrombosis during an arterial ductal stenting successfully managed by eptifibatide.

> PubMed lists PMID 34462026 in Cardiology in the young as Journal Article, with publication-date metadata of 2021-08-31 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34462026-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-05-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34462026-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-34462026-eptifibatide-v1
- Content SHA-256: `72ed73d70139dcc8a5fd087c6cfd8061704ae46a21a27749e005d2110ad96bef`

### Claims and source pins

#### Headline

Acute intraprocedural thrombosis during an arterial ductal stenting successfully managed by eptifibatide. ([`pubmed-observation-pmid-34462026-2022-05-09-c623d7bbb874`](#source-pubmed-observation-pmid-34462026-2022-05-09-c623d7bbb874))

#### Summary

PubMed lists PMID 34462026 in Cardiology in the young as Journal Article, with publication-date metadata of 2021-08-31 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34462026-2022-05-09-c623d7bbb874`](#source-pubmed-observation-pmid-34462026-2022-05-09-c623d7bbb874))

#### Paragraph 1

PubMed lists PMID 34462026 in Cardiology in the young as Journal Article, with publication-date metadata of 2021-08-31 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34462026-2022-05-09-c623d7bbb874`](#source-pubmed-observation-pmid-34462026-2022-05-09-c623d7bbb874))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34462026-2022-05-09-c623d7bbb874`](#source-pubmed-observation-pmid-34462026-2022-05-09-c623d7bbb874))

### Sources

<a id="source-pubmed-observation-pmid-34462026-2022-05-09-c623d7bbb874"></a>
- **Acute intraprocedural thrombosis during an arterial ductal stenting successfully managed by eptifibatide. · retained source version 1:2022-05-09:current:c623d7bbb874351edfec5e4d5bb7f8fb5564b8e001d2a6734876cf540c97c6df** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34462026/) (`pubmed-observation-pmid-34462026-2022-05-09-c623d7bbb874`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Acute intraprocedural thrombosis during an arterial ductal stenting successfully managed by eptifibatide." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-34462026-eptifibatide-v1 SHA-256: 72ed73d70139dcc8a5fd087c6cfd8061704ae46a21a27749e005d2110ad96bef.

---

<a id="pubmed-pmid-35926348-eptifibatide-v1"></a>

## Unraveling the role of the homoarginine residue in antiplatelet drug eptifibatide in binding to the αIIbβ3 integrin receptor.

> PubMed lists PMID 35926348 in Thrombosis research as Journal Article, with publication-date metadata of 2022-07-25 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35926348-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-07-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35926348-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-35926348-eptifibatide-v1
- Content SHA-256: `75d66089f9e2cac0cac26d369fcec52774c9a02541e8c484ee322d98e7903a14`

### Claims and source pins

#### Headline

Unraveling the role of the homoarginine residue in antiplatelet drug eptifibatide in binding to the αIIbβ3 integrin receptor. ([`pubmed-observation-pmid-35926348-2025-07-28-71806795cb0b`](#source-pubmed-observation-pmid-35926348-2025-07-28-71806795cb0b))

#### Summary

PubMed lists PMID 35926348 in Thrombosis research as Journal Article, with publication-date metadata of 2022-07-25 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35926348-2025-07-28-71806795cb0b`](#source-pubmed-observation-pmid-35926348-2025-07-28-71806795cb0b))

#### Paragraph 1

PubMed lists PMID 35926348 in Thrombosis research as Journal Article, with publication-date metadata of 2022-07-25 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35926348-2025-07-28-71806795cb0b`](#source-pubmed-observation-pmid-35926348-2025-07-28-71806795cb0b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35926348-2025-07-28-71806795cb0b`](#source-pubmed-observation-pmid-35926348-2025-07-28-71806795cb0b))

### Sources

<a id="source-pubmed-observation-pmid-35926348-2025-07-28-71806795cb0b"></a>
- **Unraveling the role of the homoarginine residue in antiplatelet drug eptifibatide in binding to the αIIbβ3 integrin receptor. · retained source version 1:2025-07-28:current:71806795cb0bd2d7a0dc524a202ee63b8954dcc47b6e36687340a546548037ce** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35926348/) (`pubmed-observation-pmid-35926348-2025-07-28-71806795cb0b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Unraveling the role of the homoarginine residue in antiplatelet drug eptifibatide in binding to the αIIbβ3 integrin receptor." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-35926348-eptifibatide-v1 SHA-256: 75d66089f9e2cac0cac26d369fcec52774c9a02541e8c484ee322d98e7903a14.

---

<a id="pubmed-pmid-36237613-eptifibatide-v1"></a>

## Eptifibatide use in ischemic stroke patients undergoing endovascular thrombectomy: A matched cohort analysis.

> PubMed lists PMID 36237613 in Frontiers in neurology as Journal Article, with publication-date metadata of 2022-09-27 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36237613-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-09-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36237613-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-36237613-eptifibatide-v1
- Content SHA-256: `4d70885d6893ef89e8a6e435b007fd48085b569219d19d4626bff67430945717`

### Claims and source pins

#### Headline

Eptifibatide use in ischemic stroke patients undergoing endovascular thrombectomy: A matched cohort analysis. ([`pubmed-observation-pmid-36237613-2024-09-05-d7ccf8df8a62`](#source-pubmed-observation-pmid-36237613-2024-09-05-d7ccf8df8a62))

#### Summary

PubMed lists PMID 36237613 in Frontiers in neurology as Journal Article, with publication-date metadata of 2022-09-27 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36237613-2024-09-05-d7ccf8df8a62`](#source-pubmed-observation-pmid-36237613-2024-09-05-d7ccf8df8a62))

#### Paragraph 1

PubMed lists PMID 36237613 in Frontiers in neurology as Journal Article, with publication-date metadata of 2022-09-27 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36237613-2024-09-05-d7ccf8df8a62`](#source-pubmed-observation-pmid-36237613-2024-09-05-d7ccf8df8a62))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36237613-2024-09-05-d7ccf8df8a62`](#source-pubmed-observation-pmid-36237613-2024-09-05-d7ccf8df8a62))

### Sources

<a id="source-pubmed-observation-pmid-36237613-2024-09-05-d7ccf8df8a62"></a>
- **Eptifibatide use in ischemic stroke patients undergoing endovascular thrombectomy: A matched cohort analysis. · retained source version 1:2024-09-05:current:d7ccf8df8a6285b695efc4cd134765524a20f5cd7fa7ca18182a9430398d02ad** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36237613/) (`pubmed-observation-pmid-36237613-2024-09-05-d7ccf8df8a62`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Eptifibatide use in ischemic stroke patients undergoing endovascular thrombectomy: A matched cohort analysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-36237613-eptifibatide-v1 SHA-256: 4d70885d6893ef89e8a6e435b007fd48085b569219d19d4626bff67430945717.

---

<a id="pubmed-pmid-36982519-eptifibatide-v1"></a>

## Eptifibatide, an Older Therapeutic Peptide with New Indications: From Clinical Pharmacology to Everyday Clinical Practice.

> PubMed lists PMID 36982519 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2023-03-13 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36982519-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-03-31
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36982519-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-36982519-eptifibatide-v1
- Content SHA-256: `f4fd174744263cbfb5e068d0cbe695277ab219af7a1f985548029c5642c3960f`

### Claims and source pins

#### Headline

Eptifibatide, an Older Therapeutic Peptide with New Indications: From Clinical Pharmacology to Everyday Clinical Practice. ([`pubmed-observation-pmid-36982519-2023-03-31-80948f8cb27c`](#source-pubmed-observation-pmid-36982519-2023-03-31-80948f8cb27c))

#### Summary

PubMed lists PMID 36982519 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2023-03-13 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36982519-2023-03-31-80948f8cb27c`](#source-pubmed-observation-pmid-36982519-2023-03-31-80948f8cb27c))

#### Paragraph 1

PubMed lists PMID 36982519 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2023-03-13 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36982519-2023-03-31-80948f8cb27c`](#source-pubmed-observation-pmid-36982519-2023-03-31-80948f8cb27c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36982519-2023-03-31-80948f8cb27c`](#source-pubmed-observation-pmid-36982519-2023-03-31-80948f8cb27c))

### Sources

<a id="source-pubmed-observation-pmid-36982519-2023-03-31-80948f8cb27c"></a>
- **Eptifibatide, an Older Therapeutic Peptide with New Indications: From Clinical Pharmacology to Everyday Clinical Practice. · retained source version 1:2023-03-31:current:80948f8cb27c44866cd7fc561a5b144ead5c78bddd81a7c9730c7306f6866b9e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36982519/) (`pubmed-observation-pmid-36982519-2023-03-31-80948f8cb27c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Eptifibatide, an Older Therapeutic Peptide with New Indications: From Clinical Pharmacology to Everyday Clinical Practice." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-36982519-eptifibatide-v1 SHA-256: f4fd174744263cbfb5e068d0cbe695277ab219af7a1f985548029c5642c3960f.

---

<a id="pubmed-pmid-41071964-eptifibatide-v1"></a>

## Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial.

> PubMed lists PMID 41071964 in Neurology as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, Comparative Study, with publication-date metadata of 2025-10-10 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41071964-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41071964-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-41071964-eptifibatide-v1
- Content SHA-256: `78a19213662c50c4ab780b9aeac14d98ccbb9a42e60ed19b3ca9ed95e6b16713`

### Claims and source pins

#### Headline

Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial. ([`pubmed-observation-pmid-41071964-2026-11-03-14ad108ef36f`](#source-pubmed-observation-pmid-41071964-2026-11-03-14ad108ef36f))

#### Summary

PubMed lists PMID 41071964 in Neurology as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, Comparative Study, with publication-date metadata of 2025-10-10 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41071964-2026-11-03-14ad108ef36f`](#source-pubmed-observation-pmid-41071964-2026-11-03-14ad108ef36f))

#### Paragraph 1

PubMed lists PMID 41071964 in Neurology as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, Comparative Study, with publication-date metadata of 2025-10-10 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41071964-2026-11-03-14ad108ef36f`](#source-pubmed-observation-pmid-41071964-2026-11-03-14ad108ef36f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41071964-2026-11-03-14ad108ef36f`](#source-pubmed-observation-pmid-41071964-2026-11-03-14ad108ef36f))

### Sources

<a id="source-pubmed-observation-pmid-41071964-2026-11-03-14ad108ef36f"></a>
- **Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial. · retained source version 1:2026-11-03:current:14ad108ef36f98cacb7a0152d36f3238bb733c16bca683c2b27ddb928e6a9646** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41071964/) (`pubmed-observation-pmid-41071964-2026-11-03-14ad108ef36f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-41071964-eptifibatide-v1 SHA-256: 78a19213662c50c4ab780b9aeac14d98ccbb9a42e60ed19b3ca9ed95e6b16713.

---

<a id="pubmed-pmid-41227129-eptifibatide-v1"></a>

## Prophylactic Intra-Arterial Eptifibatide in Stent-Assisted Coiling and Flow Diverter Treatment of Cerebral Aneurysms: A Single-Center Retrospective Analysis.

> PubMed lists PMID 41227129 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2025-10-31 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41227129-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-11-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41227129-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-41227129-eptifibatide-v1
- Content SHA-256: `ed5f7729efff7d50e0e6aa60b36101e3183154a9484e87c23fc8ad1a82bf8e31`

### Claims and source pins

#### Headline

Prophylactic Intra-Arterial Eptifibatide in Stent-Assisted Coiling and Flow Diverter Treatment of Cerebral Aneurysms: A Single-Center Retrospective Analysis. ([`pubmed-observation-pmid-41227129-2025-11-15-b598b31ba1fd`](#source-pubmed-observation-pmid-41227129-2025-11-15-b598b31ba1fd))

#### Summary

PubMed lists PMID 41227129 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2025-10-31 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41227129-2025-11-15-b598b31ba1fd`](#source-pubmed-observation-pmid-41227129-2025-11-15-b598b31ba1fd))

#### Paragraph 1

PubMed lists PMID 41227129 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2025-10-31 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41227129-2025-11-15-b598b31ba1fd`](#source-pubmed-observation-pmid-41227129-2025-11-15-b598b31ba1fd))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41227129-2025-11-15-b598b31ba1fd`](#source-pubmed-observation-pmid-41227129-2025-11-15-b598b31ba1fd))

### Sources

<a id="source-pubmed-observation-pmid-41227129-2025-11-15-b598b31ba1fd"></a>
- **Prophylactic Intra-Arterial Eptifibatide in Stent-Assisted Coiling and Flow Diverter Treatment of Cerebral Aneurysms: A Single-Center Retrospective Analysis. · retained source version 1:2025-11-15:current:b598b31ba1fd8a799a3ba3ef236a0c6c998f8294311efc0dc329beaef558a78c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41227129/) (`pubmed-observation-pmid-41227129-2025-11-15-b598b31ba1fd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Prophylactic Intra-Arterial Eptifibatide in Stent-Assisted Coiling and Flow Diverter Treatment of Cerebral Aneurysms: A Single-Center Retrospective Analysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-41227129-eptifibatide-v1 SHA-256: ed5f7729efff7d50e0e6aa60b36101e3183154a9484e87c23fc8ad1a82bf8e31.

---

<a id="pubmed-pmid-42846822-eptifibatide-v1"></a>

## Evaluation of the Rational use of Eptifibatide among Patients with Acute Coronary Syndrome Referred to Shahid Chamran Heart Hospital.

> PubMed lists PMID 42846822 in Journal of research in pharmacy practice as Journal Article, with publication-date metadata of 2026-02-24 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42846822-eptifibatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-10
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42846822-eptifibatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-42846822-eptifibatide-v1
- Content SHA-256: `a2b4e5a8f1e3638c0da1a8af6e78993a6c5deb9f428219880086b80efacb72b4`

### Claims and source pins

#### Headline

Evaluation of the Rational use of Eptifibatide among Patients with Acute Coronary Syndrome Referred to Shahid Chamran Heart Hospital. ([`pubmed-observation-pmid-42846822-2026-10-10-a3ba357a1719`](#source-pubmed-observation-pmid-42846822-2026-10-10-a3ba357a1719))

#### Summary

PubMed lists PMID 42846822 in Journal of research in pharmacy practice as Journal Article, with publication-date metadata of 2026-02-24 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42846822-2026-10-10-a3ba357a1719`](#source-pubmed-observation-pmid-42846822-2026-10-10-a3ba357a1719))

#### Paragraph 1

PubMed lists PMID 42846822 in Journal of research in pharmacy practice as Journal Article, with publication-date metadata of 2026-02-24 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42846822-2026-10-10-a3ba357a1719`](#source-pubmed-observation-pmid-42846822-2026-10-10-a3ba357a1719))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42846822-2026-10-10-a3ba357a1719`](#source-pubmed-observation-pmid-42846822-2026-10-10-a3ba357a1719))

### Sources

<a id="source-pubmed-observation-pmid-42846822-2026-10-10-a3ba357a1719"></a>
- **Evaluation of the Rational use of Eptifibatide among Patients with Acute Coronary Syndrome Referred to Shahid Chamran Heart Hospital. · retained source version 1:2026-10-10:current:a3ba357a17193d1832659e99ca63374616f42d30e7ff347adfc41c341e884241** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42846822/) (`pubmed-observation-pmid-42846822-2026-10-10-a3ba357a1719`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Evaluation of the Rational use of Eptifibatide among Patients with Acute Coronary Syndrome Referred to Shahid Chamran Heart Hospital." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/eptifibatide.json#pubmed-pmid-42846822-eptifibatide-v1 SHA-256: a2b4e5a8f1e3638c0da1a8af6e78993a6c5deb9f428219880086b80efacb72b4.

